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Appendix	1.	Innovative	risk	stratification	pathway	and	standard	care	
	
The	current	status	of	standard	care		
	
In	current	clinical	practice,	General	Practitioners	(GPs)	rely	upon	abnormal	liver	function	tests	(LFTs)	to	identify	
patients	who	may	be	at	risk	of	chronic	liver	disease.	Subsequently,	this	may	prompt	a	referral	to	secondary	care	
(Figure	1.1).		
	
Supplementary	Figure	1.1:	An	outline	of	the	standard	care	pathway	
	
Use	of	non-invasive	tests	to	identify	chronic	liver	disease	
Several	non-invasive	tests	have	been	developed	which	use	novel	imaging	techniques	or	serological	markers	to	
measure	the	amount	of	fibrosis	that	is	present	in	the	liver.	Imaging	based	modalities	such	as	transient	elastography	
(Fibroscan®,	Echosens,	Paris)	have	been	demonstrated	to	be	an	excellent	diagnostic	test	when	used	to	identify	
patients	who	may	have	significant	liver	disease	or	cirrhosis	[1].	A	Fibroscan®	calculates	the	stiffness	of	the	liver	by	
measuring	the	propagation	of	an	elastic	shear	wave	[2]	for	which	different	thresholds,	now	established	in	all	major	
aetiologies,	have	been	demonstrated	to	correlate	with	stages	of	liver	fibrosis	[3-6].		
	
Using	non-invasive	tests	to	provide	a	timely	diagnosis	for	these	patients	is	clinically	important	so	future	management	
such	as	hepatocellular	carcinoma	and	variceal	surveillance	can	be	organised	or	a	referral	for	a	liver	transplant	can	be	
planned.	Completion	of	the	test	may	also	be	the	stimulus	required	for	patients	with	milder	forms	of	fibrotic	injury	to	
alter	their	lifestyle	and	reduce	the	probability	of	their	liver	disease	progressing.		
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The	risk	stratification	pathway		
The	risk	stratification	pathway	(RSP)		encompasses	a	new	algorithm	to	target	patients	in	a	community	setting	who	
have	been	identified	to	have	a	defined	risk	factor	for	developing	chronic	liver	disease	[7].	This	includes	patients	who	
have	been	documented	to	have	hazardous	alcohol	use,	Type	2	diabetes	or	a	raised	ALT	with	no	other	cause	
identified.	A	patient’s	risk	of	chronic	liver	disease	is	subsequently	stratified	by	completion	of	a	Fibroscan®	(Figure	
1.2).	
	
A	Fibroscan®	measurement	stratifies	a	patient	to	be	at	either	low	or	high	risk	of	having	clinically	significant	liver	
disease.	Patients	at	low	risk	receive	brief	lifestyle	advice	from	the	nursing	staff	along	with	a	British	Liver	Trust	
‘Looking	After	Your	Liver’	leaflet	[8]	but	are	ultimately	discharged	back	to	the	care	of	the	GP	without	the	need	for	any	
specialist	follow	up.	Patients	at	high	risk	with	a	raised	liver	stiffness	result	are	reviewed	by	a	consultant	hepatologist	
in	the	community	and	where	appropriate	further	investigations	are	requested	or	enrolment	into	cirrhosis	
surveillance	programmes	is	organised.	Following	a	patient’s	fibroscan	and	the	results	of	any	further	investigations	a	
patient	can	be	stratified	to	have	no/mild	liver	disease,	significant	liver	disease	or	compensated	cirrhosis.		
	
Supplementary	Figure	1.2:	The	risk	stratification	pathway	 	
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Appendix	2.	Transition	probabilities	
	
Annual	probabilities	of	progression	from	undetected	fibrosis	NMD-	and	SLD-	states	
	
No	studies	were	identified	in	which	progression	probabilities	between	different	fibrosis	stages	(Stage	0	to	Stage	1,	
Stage	1	to	Stage	2,	etc.),	nor	from	NMD-	or	SLD-	states	of	disease,	were	reported	for	NAFLD.	The	identified	studies	
focused	on	long-term	mortality	in	the	NAFLD	population	(see	for	example	the	recent	study	[9])	and	could	not	be	used	
to	calculate	fibrosis	progression	probabilities.	The	only	relevant	data	were	obtained	from	a	meta-analysis	of	studies	
that	assessed	paired	liver	biopsy	specimens	to	estimate	the	rate	of	fibrosis	progression	in	patients	with	NAFLD	[10].	In	
this	meta-analysis,	annual	fibrosis	progression	rate	(FPR)	was	calculated	as	the	difference	in	fibrosis	stage	between	
the	first	and	last	biopsy	divided	by	the	time	between	biopsies	in	years,	and	a	pooled-weighted	annual	FPR	with	95%	
confidence	intervals	was	estimated.	As	the	input	parameter	to	the	model,	we	have	chosen	a	subgroup	within	the	
meta-analysis	which	best	represents	the	UK	population,	and	incorporates	NAFLD	patients	with	Stage	0	fibrosis	at	
baseline	biopsy	(see	Supplementary	Table	7	in	[10]).	Specifically,	the	meta-analysis	of	eight	studies	from	Western	
countries	was	used	in	which	the	mean	FPR	was	equal	to	0.12	(95%CI:	0.06,	0.18),	corresponding	to	one	stage	of	
progression	over	8.3	years.	In	the	absence	of	other	data,	this	estimate	was	used	to	calculate	progression	transition	
probabilities	between	NMD,	SLD,	and	CC	states,	based	on	progression	rates	between	stages	of	fibrosis,	in	the	
following	way:	
- 	time	taken	to	progress	from	Stage	0	to	Stage	4	fibrosis	was	calculated	as	33.3	years	(33.3	=	4	x	8.33=	4	x	
(1/0.12)).		
- In	accordance	with	expert	opinion	(NG,	SR,	MJ,	GA,	EW,	TD,	NT),	it	is	assumed	that	the	mean	time	taken	to	
progress	one	fibrosis	stage	is	shorter	for	more	significant	liver	disease	and	that	therefore,	the	progression	
rate	between	Stages	0	to	4		fibrosis	is	not	linear.	Hence,	employing	an	exponential	function	in	which	the	
parameter	has	been	used	based	on	expert	opinion	(NG,	SR,	MJ,	GA,	EW,	TD,	NT,	DH,	RH)	the	following	mean	
time	intervals	for	transitions	between	different	stages	of	fibrosis	was	derived,	keeping	total	time	taken	to	
progress	from	Stage	0	to	Stage	4	equal	to	33.3	years:		
• Stage	0	to	1:	14.8	years	
• Stage	1	to	2:	9.2	years	
• Stage	2	to	3:	5.7	years	
• Stage	3	to	4:	3.6	years		
	
These	intervals	were	then	used	to	obtain	the	progression	rates	between	different	stages	of	fibrosis	assuming	an	
initial	distribution	of	patients	between	fibrosis	stages	0-4	based	on	the	RSP	study	(Table	2.1.),	allowing	the	annual	
transition	probabilities	between	the	different	health	states	(NMD/SLD/CC)	to	be	calculated.	The	resultant	
probabilities	(dependent	on	the	cycle	number)	between	NMD,	SLD,	and	CC	health	states	are	presented	in	Figure	2.1.		
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Supplementary		Figure	2.1:	Annual	probability	of	progression	from	NMD-	to	SLD	state,	and	from	SLD-	to	CC	state.	
	
	
	
Supplementary	Table	2.1:	Initial	distribution	of	patients	between	fibrosis	stages	0-4	
Fibrosis	stages	 0	 1	 2	 3	 4	 Total	
%		of	patients	in	
particular	stage	
36.2%*	
	
32.8%	
	
17.2%*	
	
9.6%	
	
4.2%	
	
100%	
	
Number	of	
patients	(%)**	
149																													
(69.0%)	
58																													
(26.9%)	
9																						
(4.2%)	
216 (100%)	
*Proportion	of	patients	with	Stage	0	fibrosis	in	NMD	and	Stage	2	fibrosis	in	SLD.	(From	published	meta-analysis	-	at	baseline,	the	
distribution	of	fibrosis	for	stages	0,	1,	2,	3,	and	4	was	35.8%,	32.5%,	16.7%,	9.3%,	and	5.7%,	respectively	[10].	
**Based	on	RSP	feasibility	study	[7].	
	
Annual	probabilities	of	progression	from	undetected	fibrosis	NMD-	and	SLD-	states	are	summarized	in	Table	2.4a.		
	
	
Annual	probabilities	of	fibrosis	progression	when	the	fibrosis	stage	has	been	diagnosed	(transitions	from	
NMD+/SLD+	state)	
	
No	data	were	found	to	support	estimation	of	the	effect	of	detection	of	liver	disease	on	the	transition	probabilities	
between	NMD,	SLD	and	CC	health	states.	Despite	there	being	many	trials	studying	the	effect	of	different	treatments	
for	NAFLD	[11-13],	these	studies	report	a	change	in	mean	fibrosis	score	focusing	on	the	impact	of	intervention	on	
short-term	regression	or	stabilization	of	fibrosis/cirrhosis	rather	than	on	the	reduction	in	rate	(or	probability)	of	
fibrosis	progression.	Therefore,	from	these	studies	it	was	not	possible	to	calculate	the	transition	probabilities	for	the	
progression	of	liver	fibrosis	in	those	patients	who	are	diagnosed	and	treated.	An	individual-patient	dataset	was	
obtained	from	an	RCT	which	studied	the	histological	effect	of	rosiglitazone	in	a	NAFLD	population	(Fatty	Liver	
Improvement	with	Rosiglitazone	Therapy,	FLIRT	trial	[14]).	Sixty	three	patients	were	enrolled	(32%	patients	had	type	2	
diabetes)	all	of	whom	had	a	liver	biopsy	at	baseline	and	at	1	year.	In	this	study,	the	intervention	group	was	offered	
advice	on	lifestyle	modifications	and	treated	with	rosiglitazone	while	the	placebo	group	was	offered	advice	about	
lifestyle	modifications	only.	The	intervention	group	was	assumed	to	be	equivalent	to	the	identified/	detected	arm	
within	our	model.	As	no	specific	treatment	was	given	to	the	placebo	group	it	was	assumed	that	the	fibrosis	
progression	observed	in	this	group	would	be	equivalent	to	that	seen	in	the	unidentified/undetected	arm	within	our	
model.	Using	the	individual-patient	data	from	this	study,	patients	were	distributed	between	the	three	different	
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health	states	within	our	model	(NMD/SLD/CC)	based	upon	the	documented	fibrosis	stage	at	baseline	and	follow	up	
at	1	year.	Subsequently,	the	transition	of	patients	between	the	health	states	could	be	observed	and	the	effect	of	
rosiglitazone	on	progression	between	the	different	health	states	could	be	calculated	in	relation	to	the	placebo	group	
who	did	not	receive	this	treatment.		
	
Tables	2.2a	and	2.2b	summarise	the	transition	of	patients	in	the	intervention	and	control	groups.	
	
Supplementary	Table	2.2a:	Number	of	patients	who	transition	between	NMD	(fibrosis	stage	0-1),	SLD	(fibrosis	
stage	2-3),	CC	(fibrosis	stage	4)	health	states		in	the	intervention	group	after	1	year	(rosiglitazone,	32/63	patients,	
[14])									
Number	of	
patients	
to	NMD	 to	SLD	 to	CC	 Total	
from	NMD	 8	 4	 0	 12	
from	SLD	 4	 14	 1	 19	
from	CC	 0	 0	 1	 1	
Total	 12	 18	 2	 32	
	
	
Supplementary	Table	2.2b:	Number	of	patients	who	transition	between	NMD	(fibrosis	stage	0-1),	SLD	(fibrosis	
stage	2-3),	CC	(fibrosis	stage	4)	health	states	in	the	placebo	group	after	1	year	(31/63	patients,	[14])	
	 to	NMD	 to	SLD	 to	CC	 Total	
from	NMD	 3	 3	 0	 6	
from	SLD	 6	 16	 2	 24	
from	CC	 0	 1	 0	 1	
Total	 9	 20	 2	 31	
	
From	the	above	transition	matrices	(ignoring	regression	to	earlier	health	states)	a	relative	risk	(RR)	was	calculated	to	
reflect	the	impact	of	the	intervention	on	the	progression	of	liver	disease	between	NMD,	SLD,	and	CC	health	states	
(Table	3b):		
NMD->SLD:	(4/12)	/	(3/6)	=	0.67	[RR=0.67,	95%	CI:	0.21	to	2.07,	p=0.7]	
SLD->CC:	(1/19)	/	(2/24)	=	0.63	[RR=0.63,	95%	CI:	0.06	to	6.45,	p=0.7]	
The	RR	presented	here	reflects	the	effect	of	early	detection	and	treatment	on	clinically	significant	liver	disease	
assuming	that:	
• Lifestyle	intervention	is	offered	to	all	patients	irrespective	of	the	whether	they	are	identified	to	have	
clinically	significant	liver	disease.		
• Early	detection	leads	to	the	treatment	of	clinically	significant	NAFLD	with	a	glitazone.	
	
Rosiglitazone	was	withdrawn	from	clinical	use	in	the	UK	in	2010	due	to	an	increase	in	cardiovascular	risk	[15].	
Therefore,	we	assume	that	the	clinical	effectiveness	of	rosiglitazone	on	liver	disease	progression	is	similar	to	other	
glitazones	(e.g.	pioglitazone),	as	supported	by	published	evidence	[16,	17].	The	first	assumption	makes	the	effect	of	our	
RSP	conservative	as	it	may	be	unrealistic	to	assume	that	all	patients	in	both	RSP	and	SC	arms	will	be	offered	a	life-
style	intervention	by	the	GP.	It	is	also	unclear	if	the	effect	of	lifestyle	intervention	differs	depending	on	whether	a	
patient	is	diagnosed	with	an	invasive	investigation	in	a	hospital	setting	compared	with	a	non-invasive	test	in	the	
community.		
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In	contrast,	the	second	assumption	is	more	optimistic	as	use	of	a	glitazone	is	not	a	standard	treatment	for	all	NAFLD	
in	current	clinical	practice.	The	RCT	also	only	studied	the	histological	effects	of	treatment	over	1	year	and	this	may	
be	too	short	to	determine	whether	the	subsequent	effect	on	the	progression	of	disease	is	sustained.		
	
In	the	extension	of	this	RCT,	22	patients	continued	on	treatment	while	18	patients	who	were	initially	within	the	
placebo	group	were	started	on	rosiglitazone	at	12	months;	all	of	these	patients	were	observed	for	a	total	40	months	
[18].	In	the	first	group	the	mean	fibrosis	score	was	1.75	at	40	months,	compared	with	1.61	at	12	months	(an	increase	
of	0.14)	while	in	the	second	group	the	mean	fibrosis	score	was	1.93	at	40	months,	compared	with	1.89	at	12	months	
(an	increase	of	0.03).	This	suggests	that	the	long-term	impact	of	rosiglitazone	may	not	be	as	significant,	when	
compared	with	the	short-term	effects.		
	
Annual	probabilities	of	fibrosis	progression	when	the	fibrosis	stage	has	been	diagnosed	(transitions	from	
NMD+/SLD+	state)	are	summarized	in	Table	2.4b.		
	
	
Annual	transition	probabilities	from	significant	liver	disease	(SLD-/SLD+)	and	compensated	cirrhosis	(CC-/CC+)	to	
decompensated	cirrhosis,	HCC,	and	death	(Table	2.4a-b)	
	
Significant	liver	disease	to	HCC	
	
The	model	assumes	that	patients	can	progress	from	significant	liver	disease	(SLD-/SLD+)	to	HCC	but	no	data	to	
estimate	this	probability	was	available.	In	their	cost-utility	analysis	[16]	the	authors	calculated	the	transition	
probability	from	the	combined	health	states	of	fibrosis	stages	3	and	4	to	HCC,	based	on	a	study	of	247	NAFLD	
patients	with	fibrosis	stages	3	and	4	[19]	in	which	52.2%	had	cirrhosis	(stage	4).	Hence,	in	our	model	we	approximate	
transition	probability	from	SLD	to	HCC,	assuming	that	the	progression	probability	from	fibrosis	stage	2/3	(SLD)	is	
similar	to	progression	from	fibrosis	stage	3/4	(see	Table	2.4a-b).	
	
	
Significant	liver	disease	to	death	
	
It	is	assumed	that	mortality	from	states	NMD	and	SLD	(fibrosis	stages	0-3)	is	not	increased	due	to	liver	disease	at	this	
stage	of	the	disease.	So,	as	a	base,	age-dependent	mortality	for	the	general	population	of	England	was	assumed	for	
transition	probability	from	NMD/SLD	to	death,	and	to	account	for	higher	mortality	due	to	diabetes,	excess	mortality	
(calculated	from	diabetes-related	death	rate	of	1.4%,	from	10-year	follow-up	in	UKPDS	study	[20]		was	added	to	
general-population	mortality.	
	
	
Compensated	cirrhosis	
	
Progression	from	compensated	cirrhosis	(CC)	through	to	decompensation	and	death	were	approximated	based	on	
published	sources	and	using	expert	opinion	(Table	2.3	for	elicitation	methods	and	details	of	the	expert	panel	
members).	It	is	assumed	that	the	available	data	within	the	literature	reflects	diagnosed	cases	of	cirrhosis	(CC+)	and	
therefore	transition	probabilities	were	adjusted	for	undiagnosed	cases	of	cirrhosis	(CC-)	based	on	expert	opinion	
(Table	2.3a-b).			
	
Results	of	the	study	based	on	data	from	the	UK	Clinical	Practice	Research	Datalink	(CPRD)	for	4537	patients	
diagnosed	with	cirrhosis	between	1987	and	2002	[21]	were	used	to	estimate	transition	probabilities	between	stages	
of	cirrhosis	according	to	the	Baveno	classification	(including	decompensation).	Since	there	were	no	results	reported	
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for	NAFLD	separately,	we	used	data	for	the	non-alcohol	related	cirrhosis	subgroup,	which	accounted	for	49.2%	of	the	
cohort	(viral	hepatitis	–	5.2%,	autoimmune	liver	disease	–	1.1%,	metabolic	liver	disease	–	7.8%,	not	classified	-	
38.1%).	Annual	transition	probabilities	were	taken	from	the	probabilities	of	progression	in	the	first	year	after	
diagnosis	(reported	in	Table	2	in	[21]),	as	annual	probabilities	for	all	years	were	not	provided.	It	was	assumed	that	
these	patients	were	known	to	have	cirrhosis	(CC+).	To	approximate	transition	probabilities	from	undetected	cirrhosis	
(from	CC-)	we	used	transition	probabilities	for	CC+	adjusted	by	the	responses	of	our	panel	of	experts.	(Table	2.3).	
	
Supplementary	Table	2.3.	Responses	obtained	from	expert	panel* 
Question	related	to	NAFLD	
	
Responses	 Calculation	of	transition	
probability	
A1.	From	the	literature,	we	have	identified	the	
annual	rate	of	patients	progressing	from	
compensated	NAFLD	through	the	stages	of	the	
Baveno	classification,	to	decompensated	
NAFLD.	(Fleming	2010)	
Patients	with	Baveno	stage	1	(no	ascites,	no	
varices)	progressing	to	Baveno	stage	2	(varices,	
no	ascites)	over	the	course	of	one	year	=	32	
patients	out	of	1000.	
How	many	patients	per	year,	who	are	not	
aware	of	their	diagnosis	of	compensated	
NAFLD	would	you	expect	to	progress	from	
Baveno	stage	1	to	Baveno	stage	2?	
	
a. The	number	of	patients	progressing	
from	Baveno	stage	1	to	Baveno	stage	2	
would	stay	the	same.	
b. The	number	of	patients	progressing	
from	Baveno	stage	1	to	Baveno	stage	2	
would	increase	by	X=……..	patients,	X	<	32	
c. The	number	of	patients	progressing	
from	Baveno	stage	1	to	Baveno	stage	2	
would	double.	
40%	increase,	
16	patients	
Minimal	multiplier:	1.4	
Maximal	multiplier:	
1.5(=(16+32)/32)	
Mean	multiplier:	1.45	
	
Annual	probability	of	progression	
from	CC-	Baveno	stage	I	to	CC-	
Baveno	stage	II	was	obtained	by	
adjusting	annual	probability	of	
progression	from	CC+	Baveno	
stage	I	to	CC+	Baveno	stage	II	
using	above	multiplier.	
A2.	From	the	literature	we	have	identified	that	
6	out	of	100	patients	known	to	have	
compensated	NAFLD	will	decompensate	over	
the	course	of	1	year.	(Mahady,	2012)	
How	many	patients	out	of	100,	who	are	not	
aware	of	their	diagnosis	of	compensated	
NAFLD,	would	you	expect	to	decompensate	per	
year?	
	
a. The	number	of	patients	who	would	
decompensate	would	stay	the	same	
b. The	number	of	patients	who	would	
decompensate	would	increase	by	X=………..	
patients,	X	<	6	
c. The	number	of	patients	who	would	
3	patients,	
3	patients,														
6	patients,														
4	patients	
Minimal	multiplier:	1.5(=(3+6)/6)	
Maximal	multiplier:	2	(=(6+6)/6)	
Mean	multiplier:	1.67	
	
Annual	probability	of	progression	
from	CC-	to	DC	was	obtained	by	
adjusting	probability	of	
progression	from	CC+	to	DC	using	
above	multiplier.	
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Question	related	to	NAFLD	
	
Responses	 Calculation	of	transition	
probability	
decompensate	would	double.	
A3.	From	the	literature	we	have	identified	that	
7	out	of	100	patients,	known	to	have	
compensated	NAFLD	will	die	over	the	course	of	
1	year.	(Fleming	2010)	
What	would	you	expect	the	all-cause	mortality	
rate	to	be	for	patients	who	have	compensated	
NAFLD	but	who	are	not	aware	of	their	
diagnosis?	
	
a. The	number	of	patients	who	would	die	
would	stay	the	same.	
b. The	number	of	patients	who	would	die	
would	increase	by	X=………,	X<7	
c. The	number	of	patients	who	would	die	
would	double.	
2	patients,	
1	patient,	
7	patients,	
0.1	patients	(1	
additional	to	
70/1000)	
Minimal	multiplier:	
1.014=((0.1+7)/7)	
Maximal	multiplier:	2	(=(7+7)/7)	
Mean	multiplier:	1.36	
	
Annual	probability	of	progression	
from	CC-	to	death	was	obtained	by	
adjusting	probability	of	
progression	from	CC+	to	death	
using	above	multiplier.	
	
	
A4.	From	the	literature	we	have	identified	that	
30	out	of	1000	patients	known	to	have	
compensated	NAFLD	will	develop	a	
Hepatocellular	carcinoma	(HCC)	over	the	
course	of	1	year.	(Mahady	2012)	
How	many	patients	out	of	1000,	who	are	not	
aware	of	their	diagnosis	of	compensated	
NAFLD,	would	you	expect	to	develop	an	HCC	
per	year?	
	
a. The	number	of	patients	to	develop	an	HCC	
would	stay	the	same	
b. The	number	of	patients	to	develop	an	HCC	
would	increase	by		X=……	patients,	X<30.	
c. The	number	of	patients	to	develop	and	HCC	
would	double.	
3	patients,	
0.5	patients	(5	
additional	to	
300/1000),	
10	patients,	
1	patient,	
1	patient,	
Minimal	multiplier:	
1.033=((30+1)/30)	
Maximal	multiplier:	1.33	
(=(10+30)/30)	
Mean	multiplier:	1.10	
	
Annual	probability	of	progression	
from	CC-	to	HCC	was	obtained	by	
adjusting	probability	of	
progression	from	CC+	to	HCC	using	
above	multiplier.	
	
*Members:	Dr	Neil	Guha,	Dr	Toby	Delahooke,	Dr	Martin	James,	Dr	Stephen	Ryder,	Dr	Emilie	Wilkes	–	Nottingham	
University	Hospitals	NHS	Trust;	Dr	Nicholas	Taylor	–	Derby	Hospitals	NHS	Foundation	Trust.	
	
Compensated	cirrhosis	to	HCC	
The	transition	probability	from	compensated	cirrhosis	to	hepatoma	reported	in	a	cost-utility	analysis	[16]	which	was	
based	on	3	observational	studies	of	cirrhosis	patients		[22]	[23]	[24],	was	used	as	the	transition	probability	from	CC+	to	
HCC.	No	data	for	transition	probabilities	from	undetected	cirrhosis	(CC-)	to	HCC	were	available,	so	the	responses	of	a	
panel	of	experts	(Table	2.3)	were	used	to	approximate	the	transition	probability	CC-	to	HCC.		
	
Compensated	cirrhosis	to	death	
	
Mortality	probabilities	from	the	CC	state	were	based	on	the	result	of	the	above	mentioned	UK	population-based	
study	[21],	for	non-alcohol	related	cirrhosis,	and	it	was	assumed	that	observed	mortality	for	cirrhosis	patients	
reflected	detected	cirrhosis	(CC+).	Consequently,	to	approximate	transition	probabilities	from	undetected	cirrhosis	
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(from	CC-)	to	death	we	used	transition	probabilities	for	CC+	adjusted	by	the	responses	of	a	panel	of	experts.	(Table	
2.3).	
	
	
Transition	probabilities	for	end	stage	liver	disease	(Table	2.4c)	
	
It	is	assumed	that	progression	in	end	stage	liver	disease	is	not	affected	by	the	earlier	diagnosis	of	significant	liver	
disease	or	compensated	cirrhosis	(SLD	and	CC);	nor	by	the	earlier	identification	of	patients	with	risk	factors	for	
chronic	liver	disease	(NMD).	The	RSP	is	not	aimed	at	detecting	the	complications	of	cirrhosis	hence	for	both	the	RSP	
and	SC,	the	transition	probabilities	in	this	part	of	the	model	are	identical.	Published	studies	on	the	natural	history	of	
end	stage	liver	disease	were	used	and	where	possible	inclusion	of	data	specific	for	NAFLD	or	non-alcohol	related	
aetiologies	(see	Table	2.4c).		
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Supplementary	Table	2.4.	Transition	probabilities	
	
2.4a.	Annual	probabilities	from	undetected	fibrosis	(NMD-	and	SLD-)	and	cirrhosis	(CC-)	states	
	
Transition	 Annual	
probability	
Data	and	assumptions		 Source		
NMD-	to	SLD	 Dependent	 on	
cycle	 number	
(see	 Figure	 2.1,	
Appendix	2)	
-	Average	fibrosis	progression	rate	
(between	fibrosis	stages	0-4),	for	NAFLD	
patients,	baseline	fibrosis	stage	0,	
Western	countries	(meta-analysis	of	8	
studies):		0.12	(0.06-0.18)	[10]		
-	Assumed	exponential	decrease	of	time	
to	progression	between	subsequent	
fibrosis	stages	(see	Appendix	2)	
-	Initial	distribution	of	patients	between	
fibrosis	stages	0-4	from	feasibility	study	
and	Table	2	in		[10]		
Supplementary	
Table	7	in	[10]	and		
feasibility	study	[7]	
SLD-	to	CC	 Dependent	 on	
cycle	 number	
(see	Figure	2.1)	
SLD-	to	HCC	 0.4%	 Annual	 probability	 of	 developing	 HCC	
from	fibrosis	stages	3	or	4:	0.004	(NAFLD	
patients),	 no	 95%	 CI	 provided	 and	 no	
data	on	the	probability	of	developing	HCC	
from	fibrosis	stages	2	or	3	
Table	1	in	[16],	
calculated	from	[19]		
CC-	to	DC*	 CCI	->DCIII:	
7.3%;		
CCI->DCIV:	
1.3%;	
CCII->DCIII:	
28.5%;	
CCII->DCIV:	
8.5%	
Data	 for	detected	CC	 (CC+	 to	DC,	 see	3b	
below),	adjusted	by	expert	panel	answers	
(question	A1,	see	Table	2.3)	
[21]	 and	 expert	
panel		
CC-	to	HCC	
	
3.3%	 Data	for	detected	CC	(CC+	to	HCC,	see	1b	
below),	adjusted	by	expert	panel	answers	
(question	A4,	see	Table	2.3)	
[16]	 based	 on	 [22]	 [23]	
[24]	 and	 expert	
panel	
NMD-/SLD-										
to	death	
Probability	
dependent	on	
age		
-	 Mortality	 data	 for	 general	 population	
(life	tables	assuming	percentage	of	males	
and	initial	age	as	in	feasibility	study	[20])	
-	 Excess	 mortality	 due	 to	 diabetes	
(diabetes-related	 death	 rate	 of	 1.4%,	
from	10-year	follow-up	in	UKPDS	study)	
ONS	 (life	 tables),	
feasibility	 study	 [7],														
UKPDS	study	[20]	
	
CC-to	death*	 CCI	->death:	
10.2%;	
CCII->death:	
9.0%	
Data	 for	 detected	 CC	 (CC+	 to	 death,	 see	
3b	 below)	 adjusted	 by	 expert	 panel	
answers	(question	A2,	see	Table	2.3)	
	[21]	 and	 expert	
panel	
	
2.4b.	Annual	probabilities	from	detected	fibrosis	(NMD+	and	SLD+)	and	cirrhosis	(CC+)	states	
	
Transition	 Annual	 Data	and	assumptions	 Source	
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probability	
NMD+	to	SLD	
	
	
	
	
Table	3a	
adjusted	by	
RR=0.67	
	
	
Annual	probabilities	for	undetected	NMD	
(NMD-	to	SLD,	see	1a	above)	adjusted	by	
RR=0.67	(95%CI:	0.21	to	2.07)	from	FLIRT	
trial	 [14],	 effect	 of	 glitazone	 (see	 Tables	
2.2a	and	2.2b)	
Supplementary	
Table	 7	 in	 [10]	 and	
data	 from	 FLIRT	
trial	[14]	
	
	
	
	
	
SLD+	to	CC	
	
	
	
	
Table	3a	
adjusted	by	
RR=0.63	
	
	
Annual	 probabilities	 for	 undetected	 SLD	
(SLD-	 to	 CC,	 see	 1a	 above)	 adjusted	 by	
RR=0.63	 (95%CI:	 0.06	 to	 6.45)	 from	 [14],	
effect	 of	 glitazone	 (see	 Tables	 2.2a	 and	
2.2b)	
SLD+	to	HCC	
	
	
	
0.4%	
	
	
	
As	 in	1a	above,	assumed	to	be	the	same	
as	 annual	 probability	 SLD-	 to	 HCC	 (no	
evidence	 indicating	 the	 effect	 of	 SLD	
detection	on	HCC	development)		
Table	 1	 in	 [16],	
calculated	from	[19]		
CC+	to	DC	
	
	
	
	
	
CCI	->DCIII:	
6.4%;	
CCI->DCIV:0.8%;	
CCII->DCIII:	
17.1%;	
CCII->DCIV:	
5.1%	
Probabilities	 of	 progression	 between	
Baveno	 stages	 (I	 and	 II	 –	 compensated	
cirrhosis,	 III	 and	 IV	 –	 decompensated	
cirrhosis)	 during	 the	 1st	 year	 after	
diagnosis,	 Table	 2	 [21],	 non-alcohol	
related.	
Table	2	in	[21]	
	
	
	
	
CC+	to	HCC	
	
	
3%	
	
	
Probability	of	developing	hepatoma	from	
compensated	cirrhosis:		0.03	(0.007-0.05)	
	
[16],	calculated	from	
[22-24]	
	
NMD+/SLD+										
to	death	
	
	
	
	
	
	
Probability	
dependent	on	
age	
	
	
	
	
	
-	 Mortality	 data	 for	 general	 population	
(life	tables	assuming	percentage	of	males	
and	initial	age	as	in	feasibility	study	[7]	
-	 Excess	 mortality	 due	 to	 diabetes	
(diabetes-related	 death	 rate	 of	 1.4%,	
from	 10-year	 follow-up	 in	 UKPDS	 study)	
assumed	to	be	as	 in	4a	above	(for	NMD-	
to	death	and	for	SLD-	to	death)	
ONS	(life	tables)	,	
feasibility	study	[7],	
UKPDS	[20]	
	
	
	
	
	
CC+	to	death	
	
	
	
	
CCI	->death:	
7.5%;	
CCII->death:	
6.6%	
	
Probability	 of	 proceeding	 to	 death	
directly	 for	 patients	 with	 compensated	
cirrhosis,	 during	 the	 1st	 year	 after	
diagnosis,	non-alcohol	related	cirrhosis	
	
Table	2	in	[21]		
	
	
	
	
2.4c.	Annual	probabilities	for	end	stage	liver	disease	
	
Transition	 Annual	
probability	
Data	used	to	calculate	probability	 Source	
DC	to	HCC	
	
3%	 Probability	of	developing	hepatoma	from	
decompensated	 cirrhosis	 as	 in	 [16]	 –	 0.03	
(range:	0.007-0.05)	
	
[16],	based	on	[24]	 [23]	
[22,	25]	
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DC	to	
transplant	
Age	 <	 70:	 5%,	
age	≥	70:	0%		
Probability	 of	 liver	 transplant	 for	
decompensated	 cirrhosis	 as	 in	 [16]	 -	 0.05	
(range:	0.05-0.25)	
[16],	based	on	[26]	
DC	to	death	 DCIII	 ->death:	
25.1%;	
DCIV	->	death:	
20.4%	
Probability	 of	 proceeding	 to	 death	
directly	for	patients	with	decompensated	
cirrhosis,	 detail	 numbers	 by	 Baveno	
stages:	non-alcohol	related	disease,	Table	
2	and	3		[21],	in	the	1st	year	after	diagnosis		
[21]	
	
	
	
HCC	to	
transplant	
	
Age	<	65:	4%,	
age	≥	65:	0%		
Annual	probability	of	liver	transplant	for	
HCC	patients	in	the	two	age	groups		[27]	
[27]	
HCC	to	death	 53.0%	 -	1st	 year,	
25.5%	-	2nd	year,	
17.2%	-	3rd	year,		
16.7%	-	4th	year	
13.3%		-	after	4th		
year	
	Calculation	 based	 on	 data	 from	 the	 US	
registries:	 the	 1-,	 2-,	 3-,	 4-	 and	 5-year	
survival	 rates	 for	 the	 cohorts	 diagnosed	
in	1997-2004	years,	as	in	Table	3	in	[28]		
[28]	
Transplant	to	
death	
16.6%	-	1st	year	
3.1%	-	2nd	and	
3rd	year	
2.9%	-	after	3rd	
year	
Calculation	 based	 on	 the	 data	 published	
in	the	meta-analysis	of	9	studies,	Figure	2	
[29],	NASH	group:	598/717	(1-year	patient	
survival),	 468/598	 (3-year	 survival),	
461/625	(5-year	survival).		
[29]	
*Where	I,	II,	III,	IV	refer	to	the	four	Baveno	stages	of	cirrhosis		
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Appendix	3.	Utilities	
	
In	this	appendix,	the	review	concerning	primary	studies	on	QoL,	useful	to	obtain	utility	score,	is	summarized.	The	
focus	here	is	on	the	studies	employing	EQ-5D	tool	to	measure	QoL,	transferable	to	utility	values	in	the	UK	setting.		
To	ensure	consistency,	the	health	utility	values	for	decompensated	cirrhosis,	HCC	and	liver	transplant	have	all	been	
used	from	Chong	et	al	which	was	based	on	a	Canadian	population	and	has	clear	inputs	into	a	probabilistic	sensitivity	
analysis.	It	has	been	assumed	that	the	decrement	in	QoL	associated	with	chronic	liver	disease	is	similar	regardless	of	
the	underlying	aetiology;	the	same	assumption	was	made	in	the	cost-utility	analysis	by	Mahady	et	al	which	focused	
on	the	NAFLD	population	[16].	Chong	et	al	has	also	been	used	in	economic	evaluations	for	HCV-related	chronic	liver	
disease	[30,	31],	and	for	non-HCV	cirrhosis	[32].		
Since	the	diagnosis	of	compensated	cirrhosis	results	in	further	investigations	to	look	for	complications,	with	the	
possibility	of	subsequent	preventative	treatment,	a	utility	decrement	was	included	for	compensated	cirrhosis	once	it	
is	diagnosed	(CC+).	The	utility	score	is	assumed	to	be	equal	to	the	difference	between	the	health-related	QoL	
estimates	used	for	the	two	health	states	of	‘compensated	cirrhosis’	and	‘remaining	well	with	advanced	fibrosis	
(Fibrosis	stages	3/4)’,	in	the	cost-utility	analysis	by	Mahady	et	al.	[16]	
The	following	table	provides	the	summary	of	utility	scores	in	the	primary	studies	identified,	indicating	cost-
effectiveness	analyses	using	particular	studies.		
Supplementary	Table	3.1:	Summary	of	utility	values	for	liver	disease*		
S
t
u
d
y		
Country	 Tool	 Population	 Value	
	
CC+/C
C-		
DC	(DC)	 HCC	 LT	 PLT	
(3m)	
PLT	
(6m)	
PLT	
(1y)	
PLT	
(2y)	
CE
As		
[3
3]	
UK	 EQ-
5D	
Liver	Transplantation:	
Total	respondents	(455),	
LT(408),	PLT(48),Died	before	
LT(23),Died	after	LT(58)	
Mean	 	 	 	 	 0.64	 0.69	 0.7
1	
0.73	 [32]	
[3
4]	
Belgium	 EQ-
5D	
CHB	patients	
Total	421	,	CHB	127,	CC	69,	DC	
2,	HCC	10,	PLT	60,	ICAR	153	
Mean	
(95%	
CI)	
0.78	
(0.73
-
0.84)	
0.70	
(0.17-1)	
0.67	
(0.44-
0.90)	
	 	 	 	 0.82	
(0.7
5-
0.88
)	
[35]	
[3
6]	
Italy	 EQ-
5D	
Population	(%):	HCV(31.8),	
HBV(20.3),	Other	hep	(7.8)	
,Cirrhosis(20.4),LT(11.9),	
HCC(7.8)	
Mean	
(SE)	
0.73	
(0.27
8)	
	 0.757	
(0.327)	
0.767	
(0.256
)	
	 	 	 	 	
[3
7]	
UK	 EQ-
5D	
HCV	
population(N):	Mild	
HCV(185),Moderate	
HCV(71),Cirrhotic(40)	
Mean	 0.55	 0.45	 0.45	 	 	 	 	 	 [38]	
[3
9]	
Canada	 EQ-
5D	
HCV	population(%):	No	biopsy	
(18),	
MMHCV(23),CC(12),DC(5),HC
C(8),LT(16),	SVR	
monotherapy(19)	
Mean	
(95%	
CI)	
0.74		
(0.66
–
0.83)	
0.66		
(0.46–
0.86)	
0.65	
(0.44–
0.86)	
0.69		
(0.62–
0.77)	
	 	 	 	 [30-
32]	
[4
0]	
Several	
(reportin
g	UK	
only)	
SG	 CHB,	UK	population		 Mean	 0.66	 0.37	 0.43	 0.57	 	 	 	 0.64	 [35]	
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S
t
u
d
y		
Country	 Tool	 Population	 Value	
	
CC+/C
C-		
DC	(DC)	 HCC	 LT	 PLT	
(3m)	
PLT	
(6m)	
PLT	
(1y)	
PLT	
(2y)	
CE
As		
[4
1]	
UK	 EQ-
5D	
Population(N)	:	PBC(122),	
ALD(155),	PSC(70)	
Mean	
(95%
CI)	
	 0.49	
(SE=0.05
6)*	
0.49	
(SE=0.05
6)*	
0.51	
(0.053
)*	
0.52	
(0.06
1)*^	
	
	
^	
	
	
	
^	
	
	
	
^	
	
	
	
[38]	
*No	values	were	reported	for	NMD	–	no/mild	liver	disease	or	SLD	–	significant	liver	disease.	
CC	–	compensated	cirrhosis;	DC	–	decompensated	cirrhosis;	LT	–	liver	transplant;	PLT	–	post	liver	transplant;	CHB	-	
chronic	hepatits	B	
MMHCV	–	mild/moderate	HCV;	PBC	-	primary	biliary	cirrhosis;	ALD	-	alcoholic	liver	disease;	PSC	–	primary	sclerosing	
cholangitis;	SVR	-	sustained	virological	response;	ICAR	-	‘inactive	carrier’	[of	virus].		*Values	reported	in	[38]	obtained	
from	[41]	study.	^	Presented	in	Graph	(Figure	2)	
	 	
15	
	
Appendix	4.	Resource	use	and	costs		
	
Differences	in	resource	consumption	from	implementation	of	RSP	compared	with	SC	may	occur	due	to:	
• The	RSP	intervention;	
• Patients	being	diagnosed	with	significant	liver	disease	or	compensated	cirrhosis	(SLD+/CC+)	at	an	earlier	
stage	when	interventions	(lifestyle	modifications	+/-	treatment)	may	reduce	the	progression	of	liver	disease	
to	more	costly	health	states;	
• Positively	identifying	those	patients	who	are	at	risk	of	liver	disease	(NMD+)	and	increasing	awareness	of	how	
lifestyle	modifications	can	reduce	the	probability	of	developing	significant	liver	disease	and	thus	reducing	
the	progression	of	liver	disease	to	more	costly	health	states;	
• The	reduction	in	referrals	to	secondary	care	and	subsequent	diagnostic	tests	for	those	patients	stratified	to	
be	at	low	risk	for	chronic	liver	disease	(NMD+)	in	the	RSP	
	
	
Resource	use	data	
	
For	the	patients	who	are	identified/	detected	the	costs	for	the	NMD+/SLD+/CC+	health	states	differ	between	the	RSP	
and	SC	arms	due	to	the	specific	diagnostic	investigations	and	therapeutic	interventions	which	occur	within	each	
health	state.	E.g.	Patients	stratified	to	have	no/mild	liver	disease	(NMD+)	in	the	RSP	would	not	require	a	referral	to	
secondary	care	for	further	investigations	compared	with	the	same	patients	in	the	SC	arm	who	may	still	require	a	
referral	and	further	investigations	before	the	same	diagnosis	could	be	obtained.		It	is	also	assumed	that	patients	who	
are	unidentified/undetected	(NMD/SLD-/CC-)	accrue	no	extra	costs	in	either	of	the	RSP	or	SC	arms.		
	
Resource	use	for	each	health	state	was	derived	from	evidence	based	practice.	This	includes	evidence	from	the	
scientific	literature	along	with	local	and	national	guidelines	in	the	UK	and	clinical	practice	guidelines	from	EASL	
(European	Association	for	the	Study	of	the	Liver)	and	AASLD	(American	Association	for	the	Study	of	Liver	Disease).	
Where	limited	evidence	was	identified	within	specific	health	states,	expert	opinion	was	sought	from	a	panel	of	
regional	liver	specialists	which	has	been	previously	described.		
	
In	two	cases	there	was	disagreement	between	cost	or	resource	use	estimates	derived	from	the	literature	and	that	
reported	by	the	members	of	the	expert	panel	and	local	finance	departments.	In	such	cases,	a	range	was	used	for	the	
cost	or	resource	use	with	the	lower	and	upper	bounds	represented	by	the	two	estimates:		
	
1)	OGD:	The	cost	was	estimated	to	be	£277	based	on	NHS	reference	costs	(HRG-4	code	HRG	FZ60Z).	A	local	cost	
derived	from	an	audit	[7]	estimated	the	cost	to	be	£416.	Due	to	the	large	difference	in	estimates,	a	range	of	£277-416	
was	used	for	this	cost	item.		
	
2)	There	was	uncertainty	regarding	the	level	of	resource	used	associated	with	certain	conditions,	in	particular,	the	
number	of	inpatient	admissions	in	DC	and	the	number	of	outpatient	visits	in	DC	and	HCC.	A	range	was	constructed	
for	each	resource	use	item	based	on	the	evidence	from	a	previous	costing	study	of	liver	cirrhosis	and	information	
obtained	from	the	expert	panel	(a	detailed	breakdown	of	resource	use	in	DC	is	found	in	Tables	4.2-4.5).	
	
The	resource	use	across	the	model	states	are	described	in	the	following	subsections.	
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Resource	use	data	for	NMD	
	
In	the	RSP	arm,	patients	within	this	health	state	have	been	stratified	to	have	no/mild	liver	fibrosis	following	the	
result	of	their	fibroscan	in	primary	care.	Subsequently,	patients	diagnosed	with	NAFLD	were	assumed	to	be	referred	
to	a	dietician	and	commenced	on	pioglitazone	while	ALD	patients	were	referred	for	brief	alcohol	intervention.	A	
referral	to	secondary	care	is	not	required	and	ongoing	management	of	these	patients	can	be	completed	by	the	GP.	If	
patients	remained	in	NMD	in	subsequent	years,	they	had	a	fibroscan	repeated	every	3	years	and	an	annual	
appointment	with	their	GP.	NAFLD	patients	were	assumed	to	have	a	yearly	appointment	with	a	dietician	and	
continued	treatment	with	pioglitazone.		Two	thirds	of	ALD	patients	were	assumed	to	require	repeated	psychological	
intervention	[42]	following	failure	of	the	intervention	in	the	first	year.		
	
In	the	SC	arm	patients	were	identified	by	their	GP	following	persistently	abnormal	LFTs	and	subsequently	referred	to	
secondary	care	for	further	investigations	which	constitutes	a	full	liver	screen	(LFT,	Hepatitis	B/C	and	autoimmune	
serology)	an	ultrasound	scan,	a	fibroscan	and	a	liver	biopsy.	Following	a	histological	diagnosis	of	no/	mild	liver	
fibrosis	patients	were	assumed	to	receive	the	same	interventions	as	those	patients	in	the	RSP	arm	depending	on	the	
underlying	aetiology	of	their	liver	disease.	If	patients	remained	in	NMD	in	subsequent	years	they	were	seen	yearly	by	
the	GP	and	the	NAFLD	patients	continued	with	pioglitazone.		
	
	
Resource	use	data	for	SLD	
	
Patients	stratified	to	have	significant	liver	disease	in	the	RSP	arm	by	the	result	of	their	fibroscan	in	primary	care	were	
referred	for	further	investigations	in	secondary	care.	This	included	a	full	liver	screen,	an	ultrasound	scan	and	a	liver	
biopsy.	Patients	diagnosed	with	NAFLD	were	assumed	to	be	referred	to	a	dietician	and	commenced	on	pioglitazone	
while	ALD	patients	were	referred	for	brief	alcohol	intervention	and	commenced	on	acamprosate.	If	patients	in	the	
RSP	arm	remained	in	SLD	in	subsequent	years	it	was	assumed	they	would	continue	to	have	the	same	resource	use	
apart	from	the	initial	diagnostic	investigations.	Again	two	thirds	of	ALD	patients	would	require	repeated	
psychological	intervention.		
	
In	the	SC	arm	the	resource	use	in	the	first	year	and	the	subsequent	years	was	assumed	to	be	the	same	as	the	RSP	
arm	although	the	patients	would	have	initially	been	identified	by	their	GP	following	persistently	abnormal	LFTs	and	
only	received	their	diagnosis	following	a	referral	to	secondary	care.	Thus	the	only	difference	in	resource	use	is	an	
additional	LFT.		
	
	
Resource	use	data	for	CC	
	
Patients	stratified	to	have	compensated	cirrhosis	in	the	RSP	arm	following	their	fibroscan	in	primary	care,	were	
referred	to	secondary	care	for	further	diagnostic	investigations	and	enrolled	into	surveillance	pathways.	Thus,	along	
with	having	a	full	liver	screen,	an	ultrasound	scan	and	a	liver	biopsy	to	confirm	the	diagnosis	these	patients	would	
also	have	had	an	OGD	for	variceal	surveillance	and	a	repeat	abdominal	ultrasound	and	alpha	fetoprotein	every	6	
months	for	HCC	surveillance.	Patients	identified	to	have	varices	were	prescribed	carvedilol	as	primary	prophylaxis	for	
variceal	bleeding.	Again,	patients	diagnosed	with	NAFLD	were	also	assumed	to	be	referred	to	a	dietician	while	
patients	with	ALD	were	referred	for	a	brief	alcohol	intervention.	
	
If	patients	in	the	RSP	arm	remained	in	CC	in	subsequent	years	they	would	continue	to	have	a	six	monthly	follow-up	
in	secondary	care	along	with	an	abdominal	ultrasound	scan	and	an	alpha	fetoprotein	for	HCC	surveillance.	For	their	
variceal	surveillance	they	would	only	require	an	OGD	every	2	years.	As	in	the	previous	health	states	patients	
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diagnosed	with	NAFLD	are	assumed	to	have	a	yearly	appointment	with	a	dietician	while	two	thirds	of	patients	with	
ALD	are	referred	for	repeated	psychological	intervention.		
	
In	the	SC	arm,	resource	use	in	CC	was	assumed	to	be	the	same	as	the	RSP	arm	in	the	first	and	subsequent	years	
although	patients	would	have	initially	been	identified	differently	and	only	received	their	diagnosis	following	further	
diagnostic	investigations	in	secondary	care.	
	
	
Resource	use	data	for	DC	
	
In	the	DC	health	state,	the	resource	use	in	RSP	and	SC	arms	was	assumed	not	to	differ.	However,	there	were	large	
differences	in	the	services	used	according	to	the	decompensating	event	which	occurred;	patients	were	assumed	to	
present	with	ascites,	a	variceal	bleed	or	encephalopathy.	The	cost	for	this	health	state	was	weighted	based	on	the	
proportion	of	patients	presenting	with	each	decompensating	event	as	identified	in	d’Amico	et	al	[43].	In	this	study	
51.6%	of	patients	decompensated	with	ascites	as	their	initial	presentation,	while	22.8%	presented	with	a	variceal	
bleed	and	25.5%	presented	with	encephalopathy.	For	patients	presenting	with	a	subsequent	event	the	proportions	
were	slightly	different;	52.4%	presented	with	ascites,	18.8%	with	a	variceal	bleed,	and	28.8%	with	encephalopathy.	
The	former	was	used	in	the	cost	for	the	first	year	and	the	latter	for	the	subsequent	years	spent	in	this	health	state.	
Due	to	uncertainty	in	certain	cost	categories,	ranges	were	constructed	using	expert	opinion	and	estimates	from	
Bennett	et	al.[44].		
	
Irrespective	of	which	decompensating	event	the	patient	presented	with	all	patients	within	this	health	state	
continued	to	have	variceal	and	HCC	surveillance	and	thus	required	an	OGD	every	two	years	along	with	a	six	monthly	
alpha	fetoprotein	and	abdominal	ultrasound.	NAFLD	patients	were	assumed	to	have	an	annual	appointment	with	a	
dietician	while	ALD	patients	were	referred	for	brief	alcohol	intervention,	as	in	NMD-CC.	
	
As	previously	discussed,	there	was	uncertainty	regarding	the	number	of	inpatient	admissions	for	each	
decompensating	event	along	with	the	number	of	outpatient	visits	that	would	be	required.		Therefore,	in	agreement	
with	the	expert	panel,	a	range	was	constructed	for	patients	presenting	with	ascites	or	a	variceal	bleed	as	an	
emergency	or	planned	admission.	For	those	patients	who	presented	with	a	variceal	bleed	a	further	resource	was	
included	to	account	for	the	additional	OGDs	that	would	be	required	to	complete	endoscopic	variceal	band	ligation.	
Each	decompensating	event	was	treated	with	medications	as	detailed	in	Table	4.8.		
	
For	patients	who	remained	within	DC	the	resource	use	in	subsequent	years	remained	the	same	apart	from	those	
patients	with	ascites	who	instead	of	having	a	planned	admission	would	be	reviewed	in	the	medical	day	case	unit	for	
paracentesis	of	their	ascites.		
	
	
Resource	use	data	for	HCC	
	
As	in	the	DC	health	state,	the	resource	use	for	the	treatment	of	HCC	was	assumed	to	be	the	same	for	both	the	RSP	
and	SC	arms.	The	resource	use	varied	according	to	the	different	treatment	strategies	and	subsequently	the	cost	was	
weighted	according	to	the	proportion	of	patients	undergoing	each	treatment	identified	from	the	study	by	Schutte	et	
al[45].	In	this	study	17.7%	of	patients	underwent	surgical	resection,	6.9%	had	radiofrequency	ablation	(RFA),	32.7%	
had	transarterial	chemoembolisation	(TACE)	and	42.7%	were	prescribed	sorafenib;	a	systemic	therapy	for	patients	
who	are	not	suitable	for	surgery	or	locoregional	therapies.	The	yearly	cost	of	sorafenib	was	calculated	based	on	the	
daily	dosage	used	by	the	panel	of	experts	along	with	the	preparation	and	cost	information	from	the	British	National	
Formulary	[46].	For	patients	undergoing	a	liver	resection	an	initial	hospital	admission	and	a	planned	follow	up	
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admission	were	assumed	to	be	required	along	with	a	repeat	resection	in	17.1%	of	patients	who	would	be	identified	
to	have	tumour	recurrence	[47].	Patients	undergoing	TACE	or	RFA	had	a	hospital	day	case	admission	for	the	procedure	
and	a	planned	day	case	admission	at	follow-up.	In	agreement	with	the	expert	panel	it	was	agreed	that	all	patients	
would	have	three	follow-up	telephone	consultations	with	a	specialist	nurse	along	with	4-7	hospital	outpatient	visits.		
	
For	subsequent	years	in	both	arms	of	the	model	the	resource	use	remained	the	same	excluding	the	initial	resource	
use	and	costs	of	the	different	treatment	options	which	would	only	have	been	undertaken	during	the	first	year	
following	diagnosis.		
	
	
Resource	use	data	for	transplant	
	
The	cost	of	the	first	year	in	the	liver	transplant	health	state	was	based	on	the	only	published	study	reporting	the	cost	
of	transplant	and	follow-up	care	in	a	UK	health	setting	[48]	and	is	assumed	to	be	the	same	for	both	arms	of	the	model.		
The	cost	estimate	from	this	study	included	the	pre-transplant	work	up,	the	inpatient	admission	for	the	procedure	
and	subsequent	follow	up	care	inclusive	of	immunosuppressive	regimes	to	prevent	organ	rejection.	Thus	the	final	
cost	included	all	care	received	in	the	27	months	from	when	the	patient	was	listed	for	a	liver	transplant.			
	
Ouwens	et	al	[49]	was	the	only	study	identified	by	the	investigators	which	explicitly	reported	the	annual	cost	following	
a	liver	transplant	in	year	2	onwards	and	thus	was	used	as	the	estimate	for	the	subsequent	years	spent	in	the	liver	
transplant	state.	The	cost	for	the	first	year	was	estimated	by	subtracting	the	cost	of	Ouwens	et	al	from	the	total	cost	
of	Longworth	et	al	which	as	previously	discussed	was	based	on	a	time	period	of	27	months.	The	other	studies	
selected	by	the	investigators	were	assessed	with	the	cost	estimates	converted	to	2014	GBP	and	subsequently	used	
to	construct	a	range	for	this	health	state.	The	characteristics	of	the	studies	and	cost	estimates	in	2014	GBP	are	listed	
in	Tables	4.6-4.7.			
	
	
Source	of	unit	costs	
	
Most	of	the	unit	costs	used	to	populate	the	pathway	model	are	derived	from	NHS	reference	costs,	PSSRU	and	NHS	
pay	scales	[50,	51].	Where	a	cost	could	not	be	identified	through	UK-based	published	unit	cost	scales,	a	search	of	the	
literature	was	conducted	or	local	finance	departments	were	queried	to	obtain	the	unit	cost.	All	costs	are	inflated	to	
the	2013/14	financial	year	using	the	Department	of	Health	hospital	&	community	health	services	(HCHS)	index	[51].	
For	certain	categories,	multiple	possible	unit	costs	are	available.	In	such	cases,	the	minimum	and	maximum	costs	are	
listed.	Unit	costs	are	summarized	in	Table	4.8.	
	
	
Primary	care	
	
The	unit	cost	of	GP	and	nurse	consultation	are	sourced	from	PSSRU	2014	and	time	assumptions	from	the	GP	
workload	survey	2007	[51,	52].		
	
Secondary	care	
	
The	unit	costs	of	hospital	services	are	derived	from	NHS	reference	costs	2013/14	[50].	Cost	of	admitted	care	is	derived	
from	the	mean	cost	of	admission	(assumed	min.	length	of	stay	1	night)	and	varies	across	emergency	and	planned	
care.	Outpatient	visits	are	assumed	to	involve	a	consultant.	
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Laboratory	costs	
	
The	costs	of	laboratory	tests	and	diagnostic	scans	are	derived	from	published	studies	of	liver	disease,	published	
sources	of	unit	costs	for	the	UK	NHS	and	local	costs	quoted	by	the	finance	department.	The	cost	of	a	fibroscan	is	
derived	from	the	York	Health	Economics	evaluation	of	ultrasound	elastography	in	the	diagnosis	of	liver	fibrosis	[53].	
The	cost	of	a	fibroscan	includes	the	cost	of	an	appointment	with	a	Band	7	nurse	in	addition	to	maintenance	cost	of	
equipment.	The	cost	of	an	ultrasound,	a	liver	biopsy	and	an	OGD	are	derived	from	NHS	reference	costs	[50].	The	local	
cost	of	an	OGD	was	found	to	be	substantially	higher	than	the	national	average	(£416	vs.	£276.93);	both	are	included	
to	form	a	confidence	interval.	Unit	costs	of	LFTs,	alpha	fetoprotein	and	autoimmune	liver	screen	are	derived	from	
UK-based	published	studies.	[32,	54]	
	
	
Medications	
	
Cost	of	medications	is	derived	from	the	BNF[46].	The	cost	of	medications	used	in	a	12	month	period	was	derived	using	
information	on	daily	dose,	pack	size	and	cost	per	pack.	Details	in	Table	4.9.	
	
Other	services	
	
Patients	identified	to	be	at	risk	or	diagnosed	with	significant	liver	disease	(both	in	RSP	and	SC)	are	assumed	to	be	
referred	to	additional	services	in	the	form	of	a	dietician	appointment	(NAFLD).		
	
	
Supplementary	Table	4.1:	Summary	of	unit	costs	across	healthcare	sector	
Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
Primary	
care	
GP	clinic	visit	 46	
Based	on	patient	contact	
of	11.7	minutes	
[51]	
Secondar
y	care	
Nurse	telephone	consultation	 8.40	
Based	on	consultation	
length	of	6	mins,	band	5	
NHS	staff	earnings	
estimate	for	qualified	
nurse	
[51]	
emergency	
admission	
Liver	cirrhosis	 1685.99	
Based	on	elective	
admission,	HRG	GC17K	
NHS	reference	
costs	2013/14	[50]	
	
emergency	
admission	
Ascites	 1484.31	
Based	on	elective	
admission,	HRG	FZ91M	
[50]	
	
emergency	
admission	
Oesophageal	varices	
with	bleeding	
1317.1	
Based	on	elective	
admission,	HRG	FZ38P	
[50]	
	
emergency	
admission	
HCC	 1842.42	
Based	on	elective	
admission,	HRG	GC12K	
[50]	
	
emergency	
admission	
Encephalopathy	 2379.99	
Based	on	non-elective	
admission,	HRG	AA22G	
[50]	
	
outpatient	visit	 Liver	fibrosis,	
cirrhosis,	ascites,	
217.30	 Based	on	consultant-led	
[50]	
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Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
varices	or	HCC	–	first	
visit	
outpatient	visit,	TFC	306	
	 outpatient	visit	
Liver	fibrosis,	
cirrhosis,	ascites,	
varices	or	HCC	–	
follow-up	visit	
175.72	
Based	on	consultant-led	
outpatient	visit,	TFC	306	
[50]	
	
Planned	
admission	
Ascites	 1070.26	
Based	on	elective	
admission,	HRG	FZ91M	
[50]	
	
Planned	
admission	
Oesophageal	varices	
with	bleeding	
901.32	
Based	on	elective	
admission,	HRG	FZ38P	
[50]	
	
Planned	
admission	
Liver	cirrhosis	 1061.54	
Based	on	elective	
admission,	HRG	GC17K	
[50]	
	
Planned	
admission	
HCC	resection	 5362.01	
Based	on	elective	
admission,	HRG	GA06D	
[50]	
	
Planned	
admission	
HCC	follow-up	 1535.32	
Based	on	elective	
admission,	HRG	GC12K	
[50]	
	
Transplant	 First	year	cost	 89282	
Based	on	Longworth	et	al	
-	cost	of	first	12	months,	
inflated	to	2014	prices	
[48]	
	
Transplant	
Subsequent	years	
cost	
17077	
Based	on	Ouwens	et	al	-	
cost	in	subsequent	years,	
convered	to	GBP	and	
inflated	to	2014	prices	
[49]	
	 Day	case	
Day	case	
chemoembolisation	
(TACE)	
639.53	
Based	on	day	case	cost,	
HRG	GC12F	
[50]	
	 Day	case	 HCC	follow-up	 359.98	
Based	on	day	case,	HRG	
GC12K	
[50]	
	 Day	case	 Ascites	 400.15	
Based	on	ascites,	HRG	
FZ91M	
[50]	
	 TIPS	stent	 Variceal	bleed	 3930	 Based	on	local	cost	
Harman	et	al	-	
Economic	modelling	
of	early	TIPS	insertion	
for	acute	variceal	
haemorrhage	[55]		
Tests	
OGD	(lower	
estimate)	
	
276.93	
Based	on	outpatient	
visit,	HRG	FZ60Z	
								[50]	
	
OGD	(upper	
estimate)	
	 416	 Local	cost	estimate	
Harman	et	al	-	Economic	
modelling	of	early	TIPS	
insertion	for	acute	
variceal	haemorrhage	[55]		
	
	
Fibroscan	
	
37.30	 York	HE	Consortium:	An	Economic	Evaluation	of	
Ultrasound	Elastography	in	the	Diagnosis	of	Liver	
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Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
Fibrosis	[53]	
	
Hep	B/C	scan	
	
30	 Local	cost	estimate	
Cost	of	HCV	and	HBV	
combined	serology	
quoted	by	QMC	virology	
department		
	
liver	biopsy	
	
546.02	
Based	on	day	cost	
procedure,	HRG	
CZ36Y,	inflated	to	
2014	
						[50]	
	
Liver	function	test	 4.52	 [54]	,average	across	3	sites	
	
ultrasound	
	
49.35	
Based	on	outpatient	
visit,	HRG	RA23Z	
							[50]	
	
alpha	fetoprotein	 4.52	 [32]	
	 Autoimmune	liver	screen	 13	 Wright	et	al	(2006),	average	across	3	sites	
	
Dietician	appointment		 80	 Dietician	outpatient	visit	 [50]	
	
Hospital	transport	 231	
Based	on	NHS	ref	cost:	
ambulance	service	code	
ASS02	
[50]	
Supplementary	Table	4.2:	Breakdown	of	resource	use	and	cost	across	model	states	in	RSP,	first	year	
State Type Service Units 
Min cost 
(£) 
Max cost 
(£) 
Source 
NMD Tests Fibroscan 1 37.31 37.31 [7, 56] 
  Primary care GP appointment 1 46.00 46.00 [7] 
  
	
Dietician appointment  1 80.00 80.00 [57] 
  Medication Glitazone   19.44 19.44 [57] 
Annual  cost per patient for 
NMD state 
NAFLD 
	
182.75 182.75   
SLD Tests Liver function test 1 4.52 4.52 [58] 
  
	
Fibroscan 1 37.31 37.31 [7, 56] 
  
	
Hep B/C serology 1 30.00 30.00 [58] 
  
	
Ultrasound 1 49.35 49.35 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Consultant outpatient visit 2 393.02 393.02 [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medication‡  Glitazone  19.44 19.44 [57] 
Annual  cost per patient for SLD 
state  	
1218.65 1218.65   
CC  
  
  
  
  
Tests OGD†† 1 276.93 416 [60] 
	
Fibroscan 1 37.31 37.31 [7, 56] 
	
LFT 1 4.52 4.52 [58] 
	
Hep B/C serology 1 30.00 30.00 [58] 
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State Type Service Units 
Min cost 
(£) 
Max cost 
(£) 
Source 
  
  
  
  
	
Liver biopsy 1 546.02 546.02 [59] 
	
Ultrasound for HCC 2 98.70 98.70 [61] 
	
Alpha fetoprotein 2 9.04 9.04 [61] 
 Autoimmune liver screen 1 13.00 13.00 [58] 
Primary care GP appointment 1 46.00 46.00 [58] 
Secondary care Outpatient visits 2 393.02 393.02 [58] 
Other services Dietician appointment  1 80.00 80.00 [57] 
Medications‡   116.92 116.92 [57, 60, 62, 63] 
Annual  cost per patient for CC 
state  	
1651.46 1790.53   
DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGD for variceal bleed†† 4 1107.72 1664 
                                     
[60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
  Secondary care Emergency admission if ascites 1-3 1484.31 4452.93 [64],a 
  
	
Emergency admission of variceal 
bleed 
1-3 1317.10 3951.30 [60],a  
  
Emergency admission - 
encephalopathy 
1-3 2379.99 7139.97 [65],a 
  
	
Planned admission, ascites 0-1 0 1070.26 [44, 64] 
  
	
Planned admission, variceal bleed 0-1 0 901.32 [44],a 
  
	
Outpatient visits, ascites variceal 
bleeds or encephalopathy 
3-6 568.74 1095.90 [44],a 
  
TIPS stent – in 13% of patients with 
variceal bleed 
1 3930 3930 [55, 60] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡  NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 
Annual  cost per patient for DC 
state*  	
4221.30 9122.52   
HCC Secondary care Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission HCC resection 1 5362.01 5362.01 [44, 61, 67] 
  Hospital admission – follow-up 1 1535.32 1535.32 [44], a 
  
Day case chemoembolisation (TACE) 
or radiofrequency ablation (RFA) 
1 639.53 639.53 [44, 61, 67] 
  Day case follow-up 1 359.98 359.98 [44],a  
  
	
Outpatient visits 4-7 744.46 1271.62 [44]a 
  
	
Hospital admission - tumour 
recurrence (probability 17.1%) 
1 916.90 916.90 [47] 
  Medications Sorafenib   38879.17 38879.17 [61] 
Annual  cost per 
patient for HCC 
state**  
	 	 	
19150.55 19677.76 
	
Transplant Secondary care first year cost based on Longworth et 1 89282.20 (Range [48, 49] 
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State Type Service Units 
Min cost 
(£) 
Max cost 
(£) 
Source 
al, subtracting cost for 2nd year based 
on Ouwens et al 
56300.60,184574.29)† 
Annual  cost per 
patient for 
Transplant 
state 
      
89282.20 (Range 
56300.60,  184574.29) 
  
a:	expert	opinion	-	panel	of	hepatologists		(Dr	Neil	Guha,	Prof	Guru	Aithal,	Dr	Martin	James,	Dr	Stephen	Ryder,	Dr	
Toby	Delahooke,	Dr	Emilie	Wilkes,	Dr	Nick	Taylor)	
*	Based	on	d’Amico	et	al[68]:	ascites	51.6%,	bleeding	22.8%,	encephalopathy	25.5%.		
**	Based	on	proportion	of	patients	in	each	treatment	based	on	local	audit	data	-	surgical	resection	17.7%;	RFA	6.9%;	
TACE	32.7%;	sorafenib	42.7%	[45]		
†	Range	of	estimates	derived	from	studies	of	the	cost	of	the	transplant	and	follow-up	care	in	first	year.	Please	refer	
to	Table	8	for	estimates	and	references.	
‡	For	breakdown	of	medications	used	and	cost,	please	refer	to	Table	9	
††	Interval	based	on	cost	of	OGD:	lower	estimate	£277	based	on	NHS	reference	costs,	HRG-4	code	FZ60Z;	upper	
estimate	based	on	local	cost	found	in	Harman	et	al	[55]	of	£416.	
	
	
Supplementary	Table	4.3:	Breakdown	of	resource	use	and	cost	(£)	across	model	states	in	model,	RSP,	subsequent	
years	
State Type Service Units  
Min 
cost 
Max 
cost Source 
NMD Tests Fibroscan (every3  years)  0.333 12.43 12.43 [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medication  Glitazone   19.44 19.44 [57, 62] 
Annual  cost for NMD 
state  	
157.87 157.87   
SLD Tests Liver function test 1 4.52 4.52 a 
  
	
Fibroscan 1 37.31 37.31 a, [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Consultant outpatient visits 1 175.72 175.72 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡ Glitazone  19.44 19.44 [57, 62] 
Annual  cost for SLD 
state  	
362.99 362.99   
CC Tests OGD†† 0.5 138.47 208.00 [60] 
  
	
Fibroscan 1 37.31 37.31 [69], a 
  
	
LFT 2 9.04 9.04 a 
  
	
Ultrasound for HCC 2 98.70 98.70 [61], a 
  
	
Alpha fetoprotein 2 9.04 9.04 
                                
[61] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Outpatient visits 2 351.44 351.44 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medication‡     116.92 116.92 [60, 70] 
Annual  cost for CC 
 	
886.92 956.45   
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State Type Service Units  
Min 
cost 
Max 
cost Source 
state 
	
DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGD for variceal bleed†† 4 1107.72 1664 [60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
 Secondary care Emergency admission for ascites 1-3 1484.31 4452.93 
[64], 
a 
  Emergency admission of variceal bleed 1-3 1317.10 3951.30 
a, 
[60] 
  Emergency admission, encephalopathy 1-3 2380.00 7139.97 
[65], 
a 
  
	
Day case, ascites 6 2400.90 2400.90 
[44, 
64] 
  
	
planned admission, variceal bleeds 0-1 0 901.32 
 [44], 
a 
  
	
Oupatient visits, ascites or variceal bleeds 3-6 527.16 1054.32 
[44], 
a 
  TIPS stent – 13% of patients with variceal bleed 1 3930 3930 
[55, 
60] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡ NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 
Annual  cost for DC 
state*  	
5524.99 9887.17 
  
HCC Secondary care Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission – follow-up 1 1535.32 1535.32 
[44], 
a 
  Day case follow-up 1 359.98 359.98 
[44], 
a 
  
	
outpatient visits 4-7 702.88 1230.04 
[44], 
a 
  
	
Hospital admission - tumour recurrence 
(probability 17.1%) 
1 916.90 916.90 
[47], 
a 
  Medications  Sorafenib   38879.17 38879.17 [61] 
Annual  cost for HCC 
state** 	 	
17908.99 18436.21   
Transpla
nt 
Re-
transplantation 
Based on Longworth et al, probability 5% 
0.0
5 
4464.11 (range 2815.03,9228.71)† [48] 
 
OR subsequent 
care 
Based on Ouwens at al – prob 95% 
0.9
5 
16223.33 (range 
12733.94,16223.33)† 
[49] 
Annual  cost for transplant state***    
20687.44 (range 15548.97-
25452.04) 
  
a:	expert	opinion	-	panel	of	hepatologists	(Dr	Neil	Guha,	Prof	Guru	Aithal,	Dr	Martin	James,	Dr	Stephen	Ryder,	Dr	
Toby	Delahooke,	Dr	Emilie	Wilkes,	Dr	Nick	Taylor)	
*	Based	on	d’Amico	et	al	[68]:	ascites	52.4%,	bleeding	18.8%,	encephalopathy	28.8%.		
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**	Based	on	proportion	of	patients	in	each	treatment	based	on	local	audit	data	-	surgical	resection	17.7%;	RFA	6.9%;	
TACE	32.7%;	sorafenib	42.7%	[45]	
***	The	mean	cost	for	the	transplant	state	in	subsequent	years	was	calculated	based	on	probability	of	5%	of	
retransplantation	in	subsequent	years	after	the	first	procedure[44],	in	which	case	the	cost	for	first	year	of	transplant	
from	Longworth	et	al	[48]	would	be	applied;	in	other	cases	(probability	95%)	the	follow-up	year	cost	from	Ouwens	et	
al	[49]	would	be	applied.	
†	Range	of	estimates	derived	from	studies	of	the	cost	of	follow-up	care	in	subsequent	years.	Please	refer	to	Table	8	
for	estimates	and	references.	
‡	For	breakdown	of	medications	used	and	cost,	please	refer	to	Table	9	
††	Interval	based	on	cost	of	OGD:	lower	estimate	£277	based	on	NHS	reference	costs,	HRG-4	code	FZ60Z;	upper	
estimate	based	on	local	cost	found	in	Harman	et	al	[55]	of	£416.	
	
Supplementary	Table	4.4:	Breakdown	of	resource	use	and	cost	(£)	across	model	states,	standard	care,	first	year	
State Type Service Units Min cost Max cost Source 
NMD Tests Fibroscan 1 37.31 37.31 [57, 69] 
  LFT 2 9.04 9.04 [58] 
  Hep B/C serology 1 30.00 30.00 [58] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Ultrasound 1 49.35 49.35 [58] 
  Liver biopsy 1 546.02 546.02 [59] 
  Primary care GP appointment 1 46.00 46.00 [58] 
 Secondary care Consultant outpatient visit 2 393.02 393.02  [58] 
 Other services Dietician services  1 80.00 80.00 [57] 
  Medications     Glitazone   19.44 19.44 a, [57] 
Annual  cost for NMD 
state  	
1223.18 1223.18   
SLD Tests Liver function test 2 9.04 9.04 [58] 
  
	
Fibroscan 1 37.31 37.31 
                                      
[69] 
  
	
Hep B/C serology 1 30.00 30.00 [58] 
  
	
Ultrasound 1 49.35 49.35 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Consultant outpatient visit 2 393.02 393.02 [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡  Glitazone  19.44 19.44 [57] 
Annual  cost for SLD 
state  	
1223.18 1223.18   
CC Tests OGD 1 276.93 416 [60] 
  
	
Fibroscan 1 37.31 37.31 [69] 
  
	
LFT 2 9.04 9.04 [58] 
  
	
Hep B/C serology 1 30.00 30.00 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  
	
Ultrasound for HCC 2 98.70 98.70 [61] 
  
	
Alpha fetoprotein 2 9.04 9.04 [61] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
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State Type Service Units Min cost Max cost Source 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Outpatient visits 2 393.02 393.02 a, [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medications‡   116.92 116.92 [60, 63] 
Annual  cost for CC 
state 	 	
1655.98 1795.05   
   2354.64 2493.71  
DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGDs for variceal bleed†† 4 1107.72 1664 [60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
  Secondary care Emergency admission if ascites 1-3 1484.31 4452.93 a, [64] 
  
	
Emergency admission of variceal bleed 1-3 1317.10 3951.30 [60], a  
  
Emergency admission for 
encephalopathy 
1-3 2379.99 7139.97 [65], a 
	
  
	
Planned admission, ascites 
0
-
1 
0 1070.26 [44, 64] 
  
	
Planned admission, variceal bleed 
0
-
1 
0 901.32 [44], a 
  
	
Outpatient visits, ascites or variceal bleeds 
3
-
6 
568.74 1095.90 [44], a 
  TIPS stent - in 13% of patients with variceal bleed 1 3930 3930 [55, 60] 
  
Other 
services 
Dietician appointment  1 80.00 80.00 [57] 
 
Medicatio
ns 
NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 
Annual  cost for DC 
state*  	
4221.30 9122.52   
HCC Secondary 
care 
Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission HCC resection 1 5362.01 5362.01 [44, 61, 67] 
 Hospital admission – follow-up 1 1535.32 1535.32 [44], a 
  
Day case chemoembolisation (TACE) or radiofrequency 
ablation (RFA) 
1 639.53 639.53 [44, 61, 67] 
  Day case follow-up 1 359.98 359.98 [44], a 
  
	
Outpatient visits 
4
-
7 
744.46 1271.62 [44], a 
  
	
Hospital admission - tumour recurrence (probability 
17.1%) 
1 916.90 916.90 [47], a 
  
Medicatio
ns 
Sorafenib   38879.17 38879.17 [61] 
Annual  cost for HCC 
	 	
19150.5 19677.76   
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state** 5 
Transplant All services 
First year cost: based on Longworth et al and 
subtracting cost for 2nd year from Ouwens et al 
1 
89282.20 (Range 
56300.60,184574.29)† 
[48, 
49] 
Annual   cost  for  
transplant state 
    
89282.20(Range 
56301.60,184574.29) 
  
a:	expert	opinion	-	panel	of	hepatologists	(Dr	Neil	Guha,	Prof	Guru	Aithal,	Dr	Martin	James,	Dr	Stephen	Ryder,	Dr	
Toby	Delahooke,	Dr	Emilie	Wilkes,	Dr	Nick	Taylor)	
*	Based	on	d’Amico	et	al	[68]:	ascites	51.6%,	bleeding	22.8%,	encephalopathy	25.5%.		
**	Based	on	proportion	of	patients	in	each	treatment	based	on	local	audit	data	-	surgical	resection	17.7%;	RFA	6.9%;	
TACE	32.7%;	sorafenib	42.7%	[45]	
†	Range	of	estimates	derived	from	studies	of	the	cost	of	the	transplant	and	follow-up	care	in	first	year.	Please	refer	
to	Table	8	for	estimates	and	references.	
‡	For	breakdown	of	medications	used	and	cost,	please	refer	to	Table	9	
††	Interval	based	on	cost	of	OGD:	lower	estimate	£277	based	on	NHS	reference	costs,	HRG-4	code	FZ60Z;	upper	
estimate	based	on	local	cost	found	in	Harman	et	al	[55]	of	£416.	
	
	
Supplementary	Table	4.5:	Breakdown	of	resource	use	and	cost	(£)	across	model	states,	standard	care,	subsequent	
years	
State Type Service Units Min cost Max cost Source 
 Primary care GP visit (NAFLD)  46.00 46.00 a 
NMD Medications Glitazone (NAFLD)  19.44 19.44 a  
Annual  cost  for  NMD state 
 	
65.44 65.44   
SLD Tests Liver function test 2 9.04 9.04 a 
  
	
Fibroscan 1 37.31 37.31  [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care 
Consultant 
outpatient visits 
1 175.72 175.72 a 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
 Medications‡  Glitazone  19.44 19.44 [57] 
Annual  cost  for  SLD state  
 	
367.51 367.51   
CC Tests OGD†† 0.5 138.47 208 [60] 
  
	
LFT 2 9.04 9.04 a 
  
	
Ultrasound for 
HCC 
2 98.70 98.70 [61] 
  
	
Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Outpatient visits 2 351.44 351.44 a 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
  Medications‡     116.92 116.92 [60, 63] 
Annual  cost  for  CC state 
 	
849.61 919.14   
DC Tests OGD†† 1 276.93 416 [60] 
  
Additional OGDs 
for variceal 
4 1107.72 1664 [60] 
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State Type Service Units Min cost Max cost Source 
bleed†† 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184 184 a 
 Secondary care 
Emergency 
admission - 
ascites 
1-3 1484.31 4452.93 [64] 
  
Emergency 
admission – 
variceal bleeding 
1-3 1317.10 3951.30 [60] 
  
Emergency 
admission - 
encephalopathy 
1-3 2379.99 7139.97 [65], a 
  
	
Day case, ascites 6 2400.9 2400.9 [64], [44] 
  
	
planned 
admission, 
variceal bleeds 
0-1 0 901.32  a, [44] 
  
	
Outpatient visits, 
ascites or variceal 
bleeds 
3-6 527.16 1054.32 a, [44] 
  
TIPS stent - in 
13% of patients 
with variceal 
bleed 
1 3930 3930 [60], [55] 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
  NAFLD ascites  115.05 115.05 [64] 
 Medications‡  
NAFLD variceal 
bleeding 
 20.09 20.09 [60] 
  
NAFLD 
encephalopathy 
 3508.67 3508.67 [66] 
Annual  cost  for  DC state* 
 	
5524.99 9887.17 
	
HCC 
Secondary care Nurse telephone 
consultations 
3 25.20 25.20 a 
Hospital 
admission, follow-
up 
1 1535.32 1535.32 a, [44] 
 
Day case follow-
up 
1 359.98 359.98  
 Outpatient visits 4-7 702.88 1230.04 a, [44] 
 
Hospital 
admission - 
tumour 
recurrence 
(probability 
17.1%) 
1 916.90 916.90 [47], a 
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State Type Service Units Min cost Max cost Source 
Medications  Sorafenib   38879.17 38879.17 [61] 
Annual  cost  for  HCC state   
17908.9
9 
18436.2
1 
  
Transpla
nt 
Re-transplant OR 
subsequent care 
Based on Longworth et al 
and Ouwens et al, refer to 
Table 8 for details, 
probability 5% 
0.05 
4464.11 
(range 
2815.03,9
228.71)† 
[48], [49] 
Based on Ouwens at al – 
prob 95% 
0.95 
16223.33 
(range 
12733.94,
16223.33)
† 
[49] 
Annual  cost  for  Transplant state***     
20687.44 (range 
15548.97-25452.04) 
  
a:	expert	opinion	-	panel	of	hepatologists	(Dr	Neil	Guha,	Prof	Guru	Aithal,	Dr	Martin	James,	Dr	Stephen	Ryder,	Dr	
Toby	Delahooke,	Dr	Emilie	Wilkes,	Dr	Nick	Taylor)	
*	Based	on	d’Amico	et	al	[68]:	ascites	52.4%,	bleeding	18.8%,	encephalopathy	28.8%.		
**	Based	on	proportion	of	patients	in	each	treatment	based	on	local	audit	data	-	surgical	resection	17.7%;	RFA	6.9%;	
TACE	32.7%;	sorafenib	42.7%[45]	
***	The	mean	cost	for	the	transplant	state	in	subsequent	years	was	calculated	based	on	probability	of	5%	of	
retransplantation	in	subsequent	years	after	the	first	procedure[44],	in	which	case	the	cost	for	first	year	of	transplant	
from	Longworth	et	al[48]	would	be	applied;	in	other	cases	(probability	95%)	the	follow-up	year	cost	from	Ouwens	et	
al[49]	would	be	applied.	
†	Range	of	estimates	derived	from	studies	of	the	cost	of	the	transplant	and	follow-up	care	in	first	year.	Please	refer	
to	Table	8	for	estimates	and	references.	
‡	For	breakdown	of	medications	used	and	cost,	please	refer	to	Table	9	
††	Interval	based	on	cost	of	OGD:	lower	estimate	£277	based	on	NHS	reference	costs,	HRG-4	code	FZ60Z;	upper	
estimate	based	on	local	cost	found	in	Harman	et	al	[55]	of	£416.	
	
Supplementary	Table	4.6.	Breakdown	of	cost	studies	of	liver	transplant	used	to	derive	the	cost	for	transplant	state	
in	first	and	subsequent	years	
Study	 design	 services	 time	period	
Converted	to	
2014	GBP	
original	cost	
currency	
(year)	
Longworth	et	
al	(2003)[48]	
Prospective	cohort	 inpatient,	
outpatient,	
medications,	
other	services,	
tests	
Cost	in	first	27	
months	
106359	first	2	
years	
66,049	 GBP	(1999)	
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Study	 design	 services	 time	period	
Converted	to	
2014	GBP	
original	cost	
currency	
(year)	
Ouwens	et	al	
(2003)[49]	
Retrospective	
cohort	
hospital,	primary	
care	costs	
first	and	subsequent	
years	
84574	first	year,	
17077	subsequent	
years	
76600	first	
year;	15467	
average	for	
follow-up	years	
USD	(1992)	
Taylor	et	al	
(2002)[71]	
Retrospective	
cohort	
hospital:	
inpatient,	
medications,	
tests	
first	and	subsequent	
years	
56301	first	year,	
4615	subsequent	
years	
69892	
transplant	+	
9800	first	12	
months	follow-
up;	2nd	year	
follow-up	6533	
CAD	(1998)	
Filipponi	et	al	
(2003)[72]	
Retrospective	
cohort	
secondary	care	 cost	of	transplant	
and	initial	admission	
only	
Total	cost	
transplant	+	
follow-up,	non-
viral	80001-89958	
non-viral	
83577-93979	
EUR	(2000)	
Best	et	al	
(2001)[73]	
Retrospective	
cohort	
primary,	
secondary	care	
first	year	cost	 136382	 143363	(first	
year	cost	in	
1998,	used	
most	recent	
year	due	to	
changes	in	
clinical	practice	
over	study	
period	noted	by	
authors)	
USD	(2000)	
Lang	et	al	
(2009)[74]	
Based	on	
literature	
secondary	care	 cost	of	transplant	
and	initial	admission	
only	
184574	 247679	 USD	(2009)	
Agthoven	et	al	
(2001)[75]	
Retrospective	
cohort	
secondary	care	 cost	of	transplant	
and	initial	admission	
only	
123241	 81642	 EUR	(1996)	
van	der	Hilst	
et	al	(2008)[76]	
Meta-analysis	 secondary	care	 cost	of	transplant	
and	initial	admission	
only	
105899	for	US,	
67094	(other	
OECD	countries)	
$163438	for	US,	
$103548	(other	
OECD	countries)	
USD	(2005)	
Bennett	et	
al[44]	
Meta-analysis	 Secondary	care	 Cost	of	transplant,	
inpatient,	
outpatient	care	and	
medications	in	first	
year;	cost	of	
hospital	care	in	
subsequent	years	
95766	in	first	
year;	13404	in	
subsequent	years	
$95608	in	first	
year;	$13382	in	
subsequent	
years	
USD	(1997)	
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Study	 design	 services	 time	period	
Converted	to	
2014	GBP	
original	cost	
currency	
(year)	
Lin	et	al[77]	 Modelling	study	
(using	prospective	
and	retrospective	
previously	
collected	data)	
Secondary	care	 Cost	of	hospital	
resource	use	in	first	
and	subsequent	
years	following	
transplant	
75171	in	first	
year;	2492	in	
outpatient	care	in	
subsequent	years	
$86078	in	first	
year;	$2952	in	
outpatient	care	
in	subsequent	
years	
USD	(2003)	
	
	
Supplementary	Table	4.7.	Summary	of	cost	estimates	of	first	12	months	following	liver	transplant	(including	initial	
transplant	admission)	and	subsequent	years	
Source	 Estimate	 Notes†	
First	year	cost	
Taylor	 56301	 Cost	in	first	year	
Filipponi,	
lower	
estimate	 62924	
Cost	in	first	2	years	
minus	Ouwens	
estimate	for	2nd	year	
cost	
van	der	Hilst	 67094	 Cost	in	first	year	
Filipponi,	
upper	
estimate	 72881	
Cost	in	first	2	years	
minus	Ouwens	
estimate	for	2nd	year	
cost	
Lin	 75171	 Cost	in	first	year	
Ouwens	 84574	 Cost	in	first	year	
Longworth	 89282	
Cost	in	first	2	years	
minus	Ouwens	
estimate	for	2nd	year	
cost	
Bennett	 95766	 Cost	in	first	year	
Agthoven	 123241	 Cost	in	first	year	
Best	 136382	 Cost	in	first	year	
Lang	 184574	 Cost	in	first	year	
Cost	in	subsequent	years	
Bennett	
13404	
Cost	in	second	year,	
excluding	cost	of	
possible	re-transplant,	
already	incorporated	
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Source	 Estimate	 Notes†	
in	the	state	cost	
Ouwens	 17077	 Cost	in	second	year	
†In	certain	cases,	cost	was	calculated	based	on	multiple	sources	due	to	differences	in	length	of	follow-up	or	cost	
estimation	methods	across	individual	studies.	Some	studies	included	cost	in	the	first	2	years	following	transplant	
(e.g.	Logworth	et	al).	In	order	to	estimate	the	cost	of	first	year,	the	most	reliable	estimate	of	second	year	cost	
(Ouwens	et	al)	was	subtracted	from	2-year	estimates	
	
Supplementary	Table	4.8.	Summary	of	unit	costs	across	healthcare	sector	
Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
Primary	
care	
GP	clinic	visit	 46	
Based	on	patient	contact	
of	11.7	minutes	
[51]	
Secondar
y	care	
Nurse	telephone	consultation	 8.40	
Based	on	consultation	
length	of	6	mins,	band	5	
NHS	staff	earnings	
estimate	for	qualified	
nurse	
[51]	
emergency	
admission	
Liver	cirrhosis	 1685.99	
Based	on	elective	
admission,	HRG	GC17K	
NHS	reference	
costs	2013/14	[50]	
	
emergency	
admission	
Ascites	 1484.31	
Based	on	elective	
admission,	HRG	FZ91M	
[50]	
	
emergency	
admission	
Oesophageal	varices	
with	bleeding	
1317.1	
Based	on	elective	
admission,	HRG	FZ38P	
[50]	
	
emergency	
admission	
HCC	 1842.42	
Based	on	elective	
admission,	HRG	GC12K	
[50]	
	
emergency	
admission	
Encephalopathy	 2379.99	
Based	on	non-elective	
admission,	HRG	AA22G	
[50]	
	
outpatient	visit	
Liver	fibrosis,	
cirrhosis,	ascites,	
varices	or	HCC	–	first	
visit	
217.30	
Based	on	consultant-led	
outpatient	visit,	TFC	306	
[50]	
	 outpatient	visit	
Liver	fibrosis,	
cirrhosis,	ascites,	
varices	or	HCC	–	
follow-up	visit	
175.72	
Based	on	consultant-led	
outpatient	visit,	TFC	306	
[50]	
	
Planned	
admission	
Ascites	 1070.26	
Based	on	elective	
admission,	HRG	FZ91M	
[50]	
	
Planned	
admission	
Oesophageal	varices	
with	bleeding	
901.32	
Based	on	elective	
admission,	HRG	FZ38P	
[50]	
	
Planned	
admission	
Liver	cirrhosis	 1061.54	
Based	on	elective	
admission,	HRG	GC17K	
[50]	
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Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
	
Planned	
admission	
HCC	resection	 5362.01	
Based	on	elective	
admission,	HRG	GA06D	
[50]	
	
Planned	
admission	
HCC	follow-up	 1535.32	
Based	on	elective	
admission,	HRG	GC12K	
[50]	
	
Transplant	 First	year	cost	 89282	
Based	on	Longworth	et	al	
-	cost	of	first	12	months,	
inflated	to	2014	prices	
[48]	
	
Transplant	
Subsequent	years	
cost	
17077	
Based	on	Ouwens	et	al	-	
cost	in	subsequent	years,	
convered	to	GBP	and	
inflated	to	2014	prices	
[49]	
	 Day	case	
Day	case	
chemoembolisation	
(TACE)	
639.53	
Based	on	day	case	cost,	
HRG	GC12F	
[50]	
	 Day	case	 HCC	follow-up	 359.98	
Based	on	day	case,	HRG	
GC12K	
[50]	
	 Day	case	 Ascites	 400.15	
Based	on	ascites,	HRG	
FZ91M	
[50]	
	 TIPS	stent	 Variceal	bleed	 3930	 Based	on	local	cost	
Harman	et	al	-	
Economic	modelling	
of	early	TIPS	insertion	
for	acute	variceal	
haemorrhage	[55]		
	
Tests	
OGD	(lower	
estimate)	
	
276.93	
Based	on	outpatient	
visit,	HRG	FZ60Z	
								[50]	
	
OGD	(upper	
estimate)	
	 416	 Local	cost	estimate	
Harman	et	al	-	Economic	
modelling	of	early	TIPS	
insertion	for	acute	
variceal	haemorrhage	[55]		
	
	
Fibroscan	
	
37.30	
York	HE	Consortium:	An	Economic	Evaluation	of	
Ultrasound	Elastography	in	the	Diagnosis	of	Liver	
Fibrosis	[53]	
	
Hep	B/C	scan	
	
30	 Local	cost	estimate	
Cost	of	HCV	and	HBV	
combined	serology	
quoted	by	QMC	virology	
department		
	
liver	biopsy	
	
546.02	
Based	on	day	cost	
procedure,	HRG	
CZ36Y,	inflated	to	
2014	
						[50]	
	
Liver	function	test	 4.52	 [54]	,average	across	3	sites	
34	
	
Type	 Resource	use	 Diagnosis	 Unit	cost	 Notes	 Unit	cost	source	
	
ultrasound	
	
49.35	
Based	on	outpatient	
visit,	HRG	RA23Z	
							[50]	
	
alpha	fetoprotein	 4.52	 [32]	
	 Autoimmune	liver	screen	 13	 Wright	et	al	(2006),	average	across	3	sites	
Other	
services	
Alcohol	referral	services	IF	ALD	 778.66	
Psychological	
community-based	
programme:	£741.67	
(NICE	(2011)	-	Alcohol-
use	disorders,	inflated	
to	2014)	
[70]	
	
dietician	appointment	IF	FLD	 80	 Dietician	outpatient	visit	 [50]	
	
Hospital	transport	 231	
Based	on	NHS	ref	cost:	
ambulance	service	code	
ASS02	
[50]	
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Supplementary	Table	4.9.	Breakdown	of	the	cost	of	medications	
State	 Medication	 Dose	
Daily	
frequency	
Unit	
cost	
Pack	
supply	
Days	
supply	
Yearly	
cost	
NMD	 Pioglitazone	 30	 1	 1.49	 840	 28	 19.44	
Subtotal	 	 	 	 	 	 	 19.44	
SLD	 Pioglitazone	 30	 1	 1.49	 840	 28	 19.44	
		 Acamprosate	 666	 3	 28.92	 111888	 56	 188.63	
Subtotal	
	 	 	 	
		 		 208.06	
CC	 Carvidilol	 12.5	 1	 1.54	 350	 28	 20.09	
		 Multivitamins	 2	 1	 11.93	 90	 45	 96.83	
Subtotal	
	 	 	 	
		 		 116.92	
DC	
Carvidilol	–	
secondary	
prophylaxis	for	
variceal	bleeding	 12.5	 1	 1.54	 350	 28	 20.089	
		
Thiamine	–	
Prevention	of	
Wernicke-Korsakoff	
syndrome	 100	 1	 1.5	 2000	 20	 27.39	
		
Spironolactone	-	
ascites	 100	 2	 3.55	 2800	 14	 92.62	
		
Furosemide	-	
ascites	 40	 2	 0.86	 1120	 14	 22.44	
		
Rifaximin	-	
encephalopathy	 550	 2	 259.23	 56	 28	 3381.56	
		
Lactulose	-	
encephalopathy	 20	 3	 2.9	 500	 8.333333	 127.11	
	 NAFLD	ascites	 	 	 	 	 	 115.05	
	
NAFLD	variceal	
bleeding	 	 	 	 	 	 20.09	
	
NAFLD	
encephalopathy	 	 	 	 	 	 3508.67	
HCC	 Sorafenib	 400	 2	 2980.47	 22400	 28	 38879.17	
Subtotal	 		 		 		 		 		 		 38879.17	
Transplant	 Tacrolimus	 2	 2	 111.36	 100	 25	 1626.97	
		 Azathioprine	 100	 1	 3.54	 2800	 28	 46.18	
		 Prednisolone	 29.23	 1	 1.33	 140	 4.7896	 25.27	
Subtotal	first	year	 		 		 		
	 	
1698.42	
Subtotal	subsequent	years	 		 		 		 	 	 1626.97	
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Appendix	5.	One-way	sensitivity	analyses	
	
	
Many	of	the	model	parameters	were	subject	to	one-way	sensitivity	analysis,	using	hypothetical	increases	or	
decreases,	to	determine	the	key	drivers	of	the	model	results.	These	assumed	extreme	values	of	input	parameters.	
The	following	parameters	were	included	in	one-way	sensitivity	analyses:	
• Costs		
- transplant	(1st	and	subsequent	years),	range	as	in	Table	3		
- HCC	(1st	and	subsequent	years),	range	as	in	Table	3		
- DC	(1st	and	subsequent	years),	range	as	in	Table	3		
- NMD	in	the	RSP	(subsequent	years),	fibroscan	once	per	5	years	as	an	alternative	to	base-case	(once	per	3	
years)	
- CC	in	the	RSP	(1st	and	subsequent	years),	range	as	in	Table	3		
- CC	in	SC	(1st	and	subsequent	years),	range	as	in	Table	3		
• Utilities		
- Transplant,	limits	of	95%CI,	Table	2	
- HCC,	limits	of	95%CI,	Table	2	
- DC,	limits	of	95%CI,	Table	2	
- utility	decrement	for	cirrhosis	detection,	arbitrary	0-0.2	(see	Table	2)		
• Transition	probabilities	
- Effect	of	detection/intervention	on	fibrosis	progression,	lower	limit	of	95%CI	for	progression	rate	reduction	
(Table	2.4b	in	Appendix	2)	–	maximal	effect,	and	no	effect	(RR=1)	–	minimal	effect.	
- Effect	of	detection/intervention	on	cirrhosis	progression/mortality,		minimal	and	maximal	multipliers	based	
on	expert	panel	responses	(see	Table	2.3	in	Appendix	2)	
- Fibrosis	progression,	limits	of	95%CI,	Table	1a,	and	range	for	acceleration	of	progression	as	indicated	by	
experts	(see	Appendix	2)	
- Cirrhosis	progression/mortality,	limits	of	95%	CI	in	[21],	see	Table	2.4b	in	Appendix	2	
- Probabilities	of	detection	NMD/SLD/CC	in	RSP	and	SC,	arbitrary	increase	and	decrease	by	20	percentage	
points	(0%	assumed	if	negative	percentage).			
- Mortality	after	transplant,	alternative	value	as	in	[16]	
- Probability	of	developing	HCC	from	cirrhosis,	range	as	in	[16],	see	Table	2.4b	in	Appendix	2	
- Cut-off	age	for	transplant	from	both	DC	and	HCC,	arbitrary	from	65yrs	to	80	yrs	
	
The	detailed	assumptions	and	the	results	of	one-way	sensitivity	analyses	are	presented	in	Table	5.1.	
	
Supplementary	Table	5.	1.	Assumptions	and	results	of	one-way	sensitivity	analyses	(NAFLD	model)	
Parameter																		
(base-case	value)	
Minimal/	
maximal	/	
alternative	
value	
	
Comment	/	source	
In
cr
em
en
ta
l	
co
st
	(£
)	
In
cr
em
en
ta
l	
Q
AL
Y	
	
ICER	
(£/QALY
)	
Base	case	 512	 0.24	 2138	
Costs	(£)	
	
	
Cost	of	transplant														
	
56301	
The	lowest	estimate	identified	
[78],	see	Table	4.7		
(Appendix	4)	
512	 	
	
	
2138	
37	
	
Parameter																		
(base-case	value)	
Minimal/	
maximal	/	
alternative	
value	
	
Comment	/	source	
In
cr
em
en
ta
l	
co
st
	(£
)	
In
cr
em
en
ta
l	
Q
AL
Y	
	
ICER	
(£/QALY
)	
(1st	year),	89282	 	
184574	
	
The	 highest	 estimate	
identified	[27],	see	Table	4.7		
512	 	
	
	
	
	
	
	
	
	
	
	
0.24	
	
	
2138	
Cost	of	transplant	
(subsequent	years),	
20687	
15549		 The	 lowest	 estimated	 cost,	
see	 Tables	 4.3,	 4.5,	 and	 4.6-
4.7	
512	 2138	
25452		 The	 highest	 estimated	 cost,	
see	 Tables	 4.3,	 4.5,	 and	 4.6-
4.7	
512	 2138	
Cost	of	HCC		
(1st	year),		
19414	
19151	 Assumed	 4	 outpatient	 visits	
per	year,	see	Table	4.2		
513	 2143	
19678	 Assumed	 7	 outpatient	 visits	
per	year,	Table	4.2	
511	 2134	
Cost	of	HCC	
(subsequent	years),	
18172	
17909	 Assumed	 4	 outpatient	 visits	
per	year,	see	Table	4.3			
514	 2148	
18436	 Assumed	 7	 outpatient	 visits	
per	year,	Table	4.3	
509	 2129	
Cost	of	DC																								
(1st	year),	6672	
4221	 The	 lowest	 estimate	 (see	
Table	3)	
600	 2507	
9123	 The	 highest	 estimate	 (see	
Table	3)	
423	 1770	
Cost	of	DC																						
(subsequent	years),	
7706	
5525	 The	 lowest	 estimate	 (see	
Table	3)	
716	 2992	
9887	 The	 highest	 estimate	 (see	
Table	3)	
307	 1285	
Cost	of	NMD,	RSP	
(subsequent	years),	
158	
153	 Fibroscan	 test	 once	 per	 5	
years		
490	 2050	
Cost	of	CC,	RSP,	
1721	
1651	 	
	
	
	
The	 lowest	 and	 the	 highest	
estimate	 (see	 Table	 3	 for	
details)	
499	 2086	
1791	 524	 2191	
Cost	of	CC,	RSP	
(subsequent	years),	
921	
887	 497	 2079	
956	 526	 2200	
Cost	of	CC,	SC,		
1725	
1656	 514	 2150	
1795	 509	 2127	
Cost	of	CC,	SC	
(subsequent	years),	
884	
850	 515	 2151	
919	 508	 2125	
Utilities	
Transplant	utility,	
0.69	
0.62	 Lower	 95%CI	 limit	 [39]	 	 see	
Table	2	
	
	
 
0.24	 2138	
0.77	 Upper	 95%	 CI	 limit	 [39],	 see	 0.24	 2138	
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Parameter																		
(base-case	value)	
Minimal/	
maximal	/	
alternative	
value	
	
Comment	/	source	
In
cr
em
en
ta
l	
co
st
	(£
)	
In
cr
em
en
ta
l	
Q
AL
Y	
	
ICER	
(£/QALY
)	
Table	2	  
 
512	
HCC	utility,	0.65	 0.44	 Lower	95%CI	limit,	Table	2	 0.24	 2115	
0.86	 Upper	95%CI	limit,	Table	2		 0.24	 2163	
DC	utility,	0.66	 0.46	 Lower	95%CI	limit,	Table	2	 0.27	 1929	
0.86	 Upper	95%CI	limit,	Table	2	 0.21	 2398	
Utility	decrement	
for	detection	of	CC,	
0.1	
0	 Arbitrary	assumption	 0.29	 1789	
0.2	 Arbitrary	assumption	 0.19	 2658	
Probabilities	
Reduction	of	
progression	from	
SLD	to	CC	(relative	
risk,	RR),	0.63	
0.06	 Lower	 limit	 of	 95%CI,	 see	
Appendix	2	
-766	 0.40	 -1895	
1	 Assumed	no	effect	 971	 0.16	 5948	
Reduction	of	
progression	from	
NMD	to	SLD	
(relative	risk,	RR),	
0.67	
0.21	 Lower	 limit	 of	 95%CI,	 see	
section	Appendix	2	
-594	 0.32	 -1852	
1	 Assumed	no	effect	 1126	 0.19	 5969	
Probability	of	
decompensation	
multiplier	(CC-	to	
DC)*,	1.7	
1.5	 	
	
	
	
	
Minimal	 and	 maximal	
multipliers	 based	 on	 expert	
panel	 responses	 (see	 Table	
2.3)	
600	 0.22	 2686	
2.0	 364	 0.26	 1373	
Mortality	from	CC-	
multiplier**,	1.4	
1.0	 488	 0.24	 2069	
2.0	 549	 0.25	 2246	
Probability	of	HCC	
multiplier	(CC-	to	
HCC)***,	1.1	
1.0	 543	 0.24	 2282	
1.3	 413	 0.24	 1695	
Probability	CCI	to	
CCII	multiplier	
(undetected),	1.45	
1.4	 513	 0.24	 2144	
1.5	 510	 0.24	 2133	
Fibrosis	progression	
rate	
0.06	 Lower	95%CI	limit	in	[79]	 857	 0.12	 7032	
0.18	 Upper	95%CI	limit	in	[79]	 321	 0.35	 928	
Acceleration	of	
progression****,												
14.8	/	9.2	/	5.7	/	3.6	
13.1	/	9.2	/	
6.5	/	4.1	
The	 lowest	 acceleration	 rate	
as	indicated	by	experts	
549	 0.21	 2561	
16.5	/	9.1	/	
5.0	/	2.7	
The	highest	 	acceleration	rate	
as	indicated	by	experts	
478	 0.27	 1800	
Probability		
CCI	->DCIII,	16.4%	
14.4%	 	
	
	
	
	
	
557	 0.24	 2346	
18.5%	 470	 0.24	 1953	
CCI->DCIV,	0.8%	
	
0.4%	 525	 0.24	 2195	
1.5%	 489	 0.24	 2044	
CCII->DCIII,	17.1%	
	
13.8%	 518	 0.24	 2163	
20.8%	 506	 0.24	 2117	
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Parameter																		
(base-case	value)	
Minimal/	
maximal	/	
alternative	
value	
	
Comment	/	source	
In
cr
em
en
ta
l	
co
st
	(£
)	
In
cr
em
en
ta
l	
Q
AL
Y	
	
ICER	
(£/QALY
)	
CCII->DCIV,	5.1%	
	
3.3%	 	
	
Lower	and	upper	limits	of	95%	
CIs	in	[21]	
	
517	 0.24	 2160	
7.5%	 506	 0.24	 2115	
CCI	->death,		7.5%		
	
6.1%	 491	 0.24	 2072	
9.1%	 533	 0.24	 2207	
CCII->death,	6.6%	
	
3.9%	 509	 0.24	 2128	
10.3%	 515	 0.24	 2152	
DCIII	to	death,	
25.1%	
	
22.3%	 413	 0.23	 1783	
28.1%	 601	 0.25	 2442	
DCIV	to	death,	
20.4%	
	
16.2%	 474	 0.24	 2005	
25.2%	 543	 0.24	 2247	
CC1	to	CCIII,	3.2%	 2.3%	 515	 0.24	 2154	
4.4%	 507	 0.24	 2118	
DCIII	to	DCIV,	3.2%	 2.1%	 517	 0.24	 2158	
4.6%	 505	 0.24	 2115	
Probability	of	
detection	
NMD/SLD/CC	RSP,	
73.7%	
53.7%	 	
	
	
Arbitrary	 increase	 and	
decrease	 by	 20	 percentage	
points	 (0%	 assumed	 if	
negative	percentage).			
408	 0.20	 2032	
93.7%	 586	 0.27	 2204	
Probability	of	
detection	NMD,	SC,	
2.0%	
0%	 557	 0.25	 2265	
22.0%	 344	 0.20	 1719	
Probability	of	
detection	SLD,	SC,	
16.5%	
0%	 619	 0.35	 1773	
36.5%	 443	 0.18	 2497	
Probability	of	
detection	CC,	SC,	
8.2%	
0%	 613	 0.26	 2382	
28.2%	 313	 0.20	 1530	
Mortality	1st	year	
after	transplant,		
16.6%	
12%	 Alternative	 input	 parameter	
[16]		
512	 0.24	 2138	
Probability	CC+	to	
HCC,	3%			
0.7%	 The	minimal	value	in	[16]	 561	 0.24	 2313	
5%	 The	maximal	value	in	[16]	 467	 0.24	 1969	
Cut-off	age	for	
transition	
probability	to	
transplant	from	
both	DC	and	HCC	
65	yrs	 Assumed	 cut-off	 for	 DC	 to	
transplant	 the	 same	 as	 for	
HCC	
512	 0.24	 2138	
70	yrs	 Assumed	 cut-off	 for	 HCC	 to	
transplant	the	same	as	for	DC	
512	 0.24	 2138	
80	yrs	 Arbitrary	 -495	 0.22	 -2254	
*	Expert	panel	(see	Table	2.3).	Annual	probability	of	progression	from	CC-	to	DC	was	obtained	by	multiplying	
probability	of	progression	from	CC+	to	DC.		
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**	Expert	panel	(see	Table	2.3).	Annual	probability	of	death	from	CC-	was	obtained	by	multiplying	probability	of	
death	from	CC+.		
***	Expert	panel	(see	Table	2.3).	Annual	probability	of	HCC	from	CC-	was	obtained	by	multiplying	probability	of	HCC	
from	CC+.	
	****	Notation:	14.8	/	9.2	/	5.7	/	3.6	reflects	stage	0	to	1,	stage	1	to	2,	stage	2	to	3,	and	stage	3	to	4	mean	times	of	
progression	in	years,	respectively.		
	
To	test	the	impact	of	the	input	parameters	obtained	from	the	RSP	feasibility	study,	a	wider	one-way	sensitivity	
analysis	for	the	probabilities	of	identifying/detecting	NMD/SLD/CC	was	conducted,	to	explore	how	incremental	costs	
and	QALYs	contributed	to	overall	cost-effectiveness,	when	changing	these	detection	probabilities.	Figures	5.1,	5.2,	
and	5.3	show	incremental	cost,	effect,	and	ICER,	respectively,	for	all	possible	values	of	these	probabilities.	From	
Figure	1	we	know	that	the	life-time	incremental	cost	increases	with	detection	probability	in	the	RSP	and	decreases	
with	detection	probabilities	in	SC.	This	suggests	that	the	direct	impact	of	better	diagnostic	accuracy	in	RSP,	
compared	to	SC,	on	fibrosis/cirrhosis	management	cost	exceeds	the	lifetime	cost	savings	due	to	earlier	detection	and	
treatment	of	fibrosis/cirrhosis.	However,	the	health	benefits	of	earlier	detection	upon	RSP,	when	compared	to	SC,	
are	clear	-	both	higher	probability	of	detection	NMD/SLD/CC	in	RSP	and	lower	detection	probabilities	in	SC	lead	to	
higher	incremental	QALY	(Figure	2),	RSP	vs.	SC.	Excluding	less	favourable	case	of	worse	health	state	at	lower	costs	
(and	negative	ICERs	upon	RSP	being	dominant),	ICER	is	stable	around	1,700-2,200	£/QALY	for	the	probability	of	
NMD/SLD/CC	detection	in	RSP	ranging	from	20%	to	100%	(Figure	5.3).		
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Supplementary	Figure	5.1.	Incremental	cost	as	the	function	of	the	probability	of	fibrosis/cirrhosis	detection	in	RSP	
and	SC		
	
	
Supplementary	Figure	5.	2.	Incremental	QALY	as	the	function	of	the	probability	of	fibrosis/cirrhosis	detection	in	
RSP	and	SC		
	
Supplementary	Figure	5.3.	Incremental	cost-effectiveness	ratio	(ICER)	as	the	function	of	the	probability	of	
fibrosis/cirrhosis	detection	in	RSP	and	SC		
-400	
-300	
-200	
-100	
0	
100	
200	
300	
400	
500	
600	
700	
0	 0.2	 0.4	 0.6	 0.8	 1	
NMD,	SC	
SLD,	SC	
CC,	SC	
NMD/SLD/CC,	
RSP	
Probability	of	ﬁbrosis/cirrhosis	deteclon	
In
cr
em
en
ta
l	c
os
t	(
£)
	
-0.2	
-0.1	
0	
0.1	
0.2	
0.3	
0.4	
0	 0.2	 0.4	 0.6	 0.8	 1	
NMD,	SC	
SLD,	SC	
CC,	SC	
NMD/SLD/CC,	
RSP	
Probability	of	ﬁbrosis/cirrhosis	deteclon	
In
cr
em
en
ta
l	Q
AL
Y	
42	
	
	
	 	
-2000	
-1000	
0	
1000	
2000	
3000	
4000	
0	 0.2	 0.4	 0.6	 0.8	 1	
NMD,	SC	
SLD,	SC	
CC,	SC	
NMD/SLD/CC,	
RSP	
Probability	of	ﬁbrosis/cirrhosis	deteclon	I
nc
re
m
en
ta
l	c
os
t-
eﬀ
ec
lv
en
es
s	r
al
o	
			
			
			
			
			
			
			
			
			
			
			
			
(IC
ER
),	
£/
Q
AL
Y	
43	
	
References	
1.	Friedrich-Rust	M,	Ong	MF,	Martens	S,	Sarrazin	C,	Bojunga	J,	Zeuzem	S,	et	al.	Performance	of	transient	
elastography	for	the	staging	of	liver	fibrosis:	a	meta-analysis.	Gastroenterology	2008;	134(4):960-974.	
2.	Sandrin	L,	Fourquet	B,	Hasquenoph	JM,	Yon	S,	Fournier	C,	Mal	F,	et	al.	Transient	elastography:	a	new	noninvasive	
method	for	assessment	of	hepatic	fibrosis.	Ultrasound	in	medicine	&	biology	2003;	29(12):1705-1713.	
3.	Nguyen-Khac	E,	Chatelain	D,	Tramier	B,	Decrombecque	C,	Robert	B,	Joly	JP,	et	al.	Assessment	of	asymptomatic	
liver	fibrosis	in	alcoholic	patients	using	fibroscan:	prospective	comparison	with	seven	non-invasive	laboratory	
tests.	Alimentary	Pharmacology	&	Therapeutics	2008;	28(10):1188-1198.	
4.	Roulot	D,	Czernichow	S,	Le	Clesiau	H,	Costes	JL,	Vergnaud	AC,	Beaugrand	M.	Liver	stiffness	values	in	apparently	
healthy	subjects:	influence	of	gender	and	metabolic	syndrome.	J	Hepatol	2008;	48(4):606-613.	
5.	Wong	VW,	Vergniol	J,	Wong	GL,	Foucher	J,	Chan	HL,	Le	Bail	B,	et	al.	Diagnosis	of	fibrosis	and	cirrhosis	using	liver	
stiffness	measurement	in	nonalcoholic	fatty	liver	disease.	Hepatology	(Baltimore,	Md)	2010;	51(2):454-462.	
6.	Myers	RP,	Pomier-Layrargues	G,	Kirsch	R,	Pollett	A,	Duarte-Rojo	A,	Wong	D,	et	al.	Feasibility	and	diagnostic	
performance	of	the	FibroScan	XL	probe	for	liver	stiffness	measurement	in	overweight	and	obese	patients.	
Hepatology	(Baltimore,	Md)	2012;	55(1):199-208.	
7.	Harman	DJ,	Ryder	SD,	James	MW,	Jelpke	M,	Ottey	DS,	Wilkes	EA,	et	al.	Direct	targeting	of	risk	factors	significantly	
increases	the	detection	of	liver	cirrhosis	in	primary	care:	a	cross-sectional	diagnostic	study	utilising	transient	
elastography.	BMJ	Open	2015;	5(4):e007516.	
8.	BLT.	Love	Your	Liver.	A	British	Liver	Trust	Campaign:	to	pioneer	liver	health.	In:	wwwbritishlivertrustorguk;	2012.	
9.	Ekstedt	M,	Hagstrom	H,	Nasr	P,	Fredrikson	M,	Stal	P,	Kechagias	S,	et	al.	Fibrosis	stage	is	the	strongest	predictor	
for	disease-specific	mortality	in	NAFLD	after	up	to	33	years	of	follow-up.	Hepatology	(Baltimore,	Md)	2015;	
61(5):1547-1554.	
10.	Singh	S,	Allen	AM,	Wang	Z,	Prokop	LJ,	Murad	MH,	Loomba	R.	Fibrosis	progression	in	nonalcoholic	fatty	liver	vs	
nonalcoholic	steatohepatitis:	a	systematic	review	and	meta-analysis	of	paired-biopsy	studies.	Clinical	
gastroenterology	and	hepatology	:	the	official	clinical	practice	journal	of	the	American	Gastroenterological	
Association	2015;	13(4):643-654	e641-649;	quiz	e639-640.	
11.	Adams	LA,	Harmsen	S,	St	Sauver	JL,	Charatcharoenwitthaya	P,	Enders	FB,	Therneau	T,	et	al.	Nonalcoholic	fatty	
liver	disease	increases	risk	of	death	among	patients	with	diabetes:	a	community-based	cohort	study.	American	
Journal	of	Gastroenterology	2010;	105(7):1567-1573.	
12.	Wong	RJ,	Aguilar	M,	Cheung	R,	Perumpail	RB,	Harrison	SA,	Younossi	ZM,	et	al.	Nonalcoholic	steatohepatitis	is	
the	second	leading	etiology	of	liver	disease	among	adults	awaiting	liver	transplantation	in	the	United	States.	
Gastroenterology	2015;	148(3):547-555.	
13.	Wong	VW,	Wong	GL,	Choi	PC,	Chan	AW,	Li	MK,	Chan	HY,	et	al.	Disease	progression	of	non-alcoholic	fatty	liver	
disease:	a	prospective	study	with	paired	liver	biopsies	at	3	years.	Gut	2010;	59(7):969-974.	
14.	Ratziu	V,	Giral	P,	Jacqueminet	S,	Charlotte	F,	Hartemann–Heurtier	A,	Serfaty	L,	et	al.	Rosiglitazone	for	
Nonalcoholic	Steatohepatitis:	One-Year	Results	of	the	Randomized	Placebo-Controlled	Fatty	Liver	Improvement	
With	Rosiglitazone	Therapy	(FLIRT)	Trial.	Gastroenterology	2008;	135(1):100-110.	
15.	Kon	P.	Avandia	and	Avandamet	(rosiglitazone).	Suspension	of	marketing:	benefits	no	longer	outweigh	risks.	
Letter	for	healthcare	professionals.	
http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/Safetyinformation/Safetywa
rningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofession
alsonthesafetyofmedicines/CON096743.	Last	accessed	11/03/2016.	2010.	
16.	Mahady	SE,	Wong	G,	Craig	JC,	George	J.	Pioglitazone	and	vitamin	E	for	nonalcoholic	steatohepatitis:	A	cost	
utility	analysis.	Hepatology	(Baltimore,	Md)	2012;	56(6):2172-2179.	
17.	Musso	G,	Gambino	R,	Cassader	M,	Pagano	G.	A	meta-analysis	of	randomized	trials	for	the	treatment	of	
nonalcoholic	fatty	liver	disease.	Hepatology	2010;	52(1):79-104.	
44	
	
18.	Ratziu	V,	Charlotte	F,	Bernhardt	C,	Giral	P,	Halbron	M,	LeNaour	G,	et	al.	Long-term	efficacy	of	rosiglitazone	in	
nonalcoholic	steatohepatitis:	Results	of	the	fatty	liver	improvement	by	rosiglitazone	therapy	(FLIRT	2)	extension	
trial.	Hepatology	2010;	51(2):445-453.	
19.	Bhala	N,	Angulo	P,	van	der	Poorten	D,	Lee	E,	Hui	JM,	Saracco	G,	et	al.	The	natural	history	of	nonalcoholic	fatty	
liver	disease	with	advanced	fibrosis	or	cirrhosis:	An	international	collaborative	study.	Hepatology	2011;	
54(4):1208-1216.	
20.	Holman	RR,	Paul	SK,	Bethel	MA,	Matthews	DR,	Neil	HAW.	10-Year	Follow-up	of	Intensive	Glucose	Control	in	
Type	2	Diabetes.	New	England	Journal	of	Medicine	2008;	359(15):1577-1589.	
21.	Fleming	KM,	Aithal	GP,	Card	TR,	West	J.	The	rate	of	decompensation	and	clinical	progression	of	disease	in	
people	with	cirrhosis:	a	cohort	study.	Alimentary	pharmacology	&	therapeutics	2010;	32(11-12):1343-1350.	
22.	Sanyal	AJ,	Banas	C,	Sargeant	C,	Luketic	VA,	Sterling	RK,	Stravitz	RT,	et	al.	Similarities	and	differences	in	outcomes	
of	cirrhosis	due	to	nonalcoholic	steatohepatitis	and	hepatitis	C.	Hepatology	2006;	43(4):682-689.	
23.	Ascha	MS,	Hanouneh	IA,	Lopez	R,	Tamimi	TA-R,	Feldstein	AF,	Zein	NN.	The	incidence	and	risk	factors	of	
hepatocellular	carcinoma	in	patients	with	nonalcoholic	steatohepatitis.	Hepatology	2010;	51(6):1972-1978.	
24.	Ratziu	V,	Bonyhay	L,	Di	Martino	V,	Charlotte	F,	Cavallaro	L,	Sayegh-Tainturier	M-H,	et	al.	Survival,	liver	failure,	
and	hepatocellular	carcinoma	in	obesity-related	cryptogenic	cirrhosis.	Hepatology	2002;	35(6):1485-1493.	
25.	Yatsuji	S,	Hashimoto	E,	Tobari	M,	Taniai	M,	Tokushige	K,	Shiratori	K.	Clinical	features	and	outcomes	of	cirrhosis	
due	to	non-alcoholic	steatohepatitis	compared	with	cirrhosis	caused	by	chronic	hepatitis	C.	Journal	of	
Gastroenterology	and	Hepatology	2009;	24(2):248-254.	
26.	Perry	JF,	Charlton	B,	Koorey	DJ,	Waugh	RC,	Gallagher	PJ,	Crawford	MD,	et	al.	Outcome	of	patients	with	
hepatocellular	carcinoma	referred	to	a	tertiary	centre	with	availability	of	multiple	treatment	options	including	
cadaveric	liver	transplantation.	Liver	International	2007;	27(9):1240-1248.	
27.	Lang	K,	Danchenko	N,	Gondek	K,	Shah	S,	Thompson	D.	The	burden	of	illness	associated	with	hepatocellular	
carcinoma	in	the	United	States.	Journal	of	Hepatology;	50(1):89-99.	
28.	Altekruse	SF,	McGlynn	KA,	Reichman	ME.	Hepatocellular	Carcinoma	Incidence,	Mortality,	and	Survival	Trends	in	
the	United	States	From	1975	to	2005.	Journal	of	Clinical	Oncology	2009;	27(9):1485-1491.	
29.	Wang	X,	Li	J,	Riaz	DR,	Shi	G,	Liu	C,	Dai	Y.	Outcomes	of	Liver	Transplantation	for	Nonalcoholic	Steatohepatitis:	A	
Systematic	Review	and	Meta-analysis.	Clinical	Gastroenterology	and	Hepatology;	12(3):394-402.e391.	
30.	Liu	S,	Schwarzinger	M,	Carrat	F,	Goldhaber-Fiebert	JD.	Cost	effectiveness	of	fibrosis	assessment	prior	to	
treatment	for	chronic	hepatitis	C	patients.	PLoS	One	2011;	6(12):e26783.	
31.	Liu	S,	Cipriano	LE,	Holodniy	M,	Owens	DK,	Goldhaber-Fiebert	JD.	New	protease	inhibitors	for	the	treatment	of	
chronic	hepatitis	C:	a	cost-effectiveness	analysis.	Ann	Intern	Med	2012;	156(4):279-290.	
32.	Thompson	Coon	J,	Rogers	G,	Hewson	P,	Wright	D,	Anderson	R,	Cramp	M,	et	al.	Surveillance	of	cirrhosis	for	
hepatocellular	carcinoma:	systematic	review	and	economic	analysis.	Health	technology	assessment	2007;	11(34):1-
206.	
33.	Ratcliffe	J,	Longworth	L,	Young	T,	Bryan	S,	Burroughs	A,	Buxton	M.	Assessing	health-related	quality	of	life	pre-	
and	post-liver	transplantation:	a	prospective	multicenter	study.	Liver	transplantation	:	official	publication	of	the	
American	Association	for	the	Study	of	Liver	Diseases	and	the	International	Liver	Transplantation	Society	2002;	
8(3):263-270.	
34.	Schwierz	CT,	N.;	Van	De	Sande,	S.;	Mohamed,	G.;	Frederik,	N.	;Colle,	I.;	Yvres,	H.	;Hulstaert,	F.;.	Economic	
evaluation	of	antiviral	treatment	of	chronic	hepatitis	B	in	Belgium	–	Part	2.	Health	Technology	Assessment	(HTA).	
In;	2010.	
35.	Hulstaert	F,	Schwierz	C,	Nevens	F,	Thiry	N,	Gamil	M,	Colle	I,	et	al.	Should	chronic	hepatitis	B	be	treated	as	early	
as	possible?	International	journal	of	technology	assessment	in	health	care	2013;	29(1):35-41.	
36.	Scalone	L,	Ciampichini	R,	Fagiuoli	S,	Gardini	I,	Fusco	F,	Gaeta	L,	et	al.	Comparing	the	performance	of	the	
standard	EQ-5D	3L	with	the	new	version	EQ-5D	5L	in	patients	with	chronic	hepatic	diseases.	Quality	of	life	research	
:	an	international	journal	of	quality	of	life	aspects	of	treatment,	care	and	rehabilitation	2013;	22(7):1707-1716.	
45	
	
37.	Wright	M,	Grieve	R,	Roberts	J,	Main	J,	Thomas	HC.	Health	benefits	of	antiviral	therapy	for	mild	chronic	hepatitis	
C:	randomised	controlled	trial	and	economic	evaluation.	Health	technology	assessment	(Winchester,	England)	2006;	
10(21):1-113,	iii.	
38.	Tsochatzis	EA,	Crossan	C,	Longworth	L,	Gurusamy	K,	Rodriguez-Peralvarez	M,	Mantzoukis	K,	et	al.	Cost-
effectiveness	of	noninvasive	liver	fibrosis	tests	for	treatment	decisions	in	patients	with	chronic	hepatitis	C.	
Hepatology	(Baltimore,	Md)	2014;	60(3):832-843.	
39.	Chong	CA,	Gulamhussein	A,	Heathcote	EJ,	Lilly	L,	Sherman	M,	Naglie	G,	et	al.	Health-state	utilities	and	quality	of	
life	in	hepatitis	C	patients.	The	American	journal	of	gastroenterology	2003;	98(3):630-638.	
40.	Levy	AR,	Kowdley	KV,	Iloeje	U,	Tafesse	E,	Mukherjee	J,	Gish	R,	et	al.	The	impact	of	chronic	hepatitis	B	on	quality	
of	life:	a	multinational	study	of	utilities	from	infected	and	uninfected	persons.	Value	in	health	:	the	journal	of	the	
International	Society	for	Pharmacoeconomics	and	Outcomes	Research	2008;	11(3):527-538.	
41.	Longworth	L,	Young	T,	Buxton	MJ,	Ratcliffe	J,	Neuberger	J,	Burroughs	A,	et	al.	Midterm	cost-effectiveness	of	the	
liver	transplantation	program	of	England	and	Wales	for	three	disease	groups.	Liver	transplantation	:	official	
publication	of	the	American	Association	for	the	Study	of	Liver	Diseases	and	the	International	Liver	Transplantation	
Society	2003;	9(12):1295-1307.	
42.	NICE.	Alcohol-use	disorders:	alcohol	dependence.	In:	Costing	report;	2011.	
43.	D'Amico	G,	Garcia-Tsao	G,	Pagliaro	L.	Natural	history	and	prognostic	indicators	of	survival	in	cirrhosis:	a	
systematic	review	of	118	studies.	Journal	of	hepatology	2006;	44(1):217-231.	
44.	Bennett	WG,	Inoue	Y,	Beck	JR,	Wong	JB,	Pauker	SG,	Davis	GL.	Estimates	of	the	cost-effectiveness	of	a	single	
course	of	interferon-alpha	2b	in	patients	with	histologically	mild	chronic	hepatitis	C.	Annals	of	internal	medicine	
1997;	127(10):855-865.	
45.	Schutte	K,	Schulz	C,	Poranzke	J,	Antweiler	K,	Bornschein	J,	Bretschneider	T,	et	al.	Characterization	and	prognosis	
of	patients	with	hepatocellular	carcinoma	(HCC)	in	the	non-cirrhotic	liver.	BMC	gastroenterology	2014;	14:117.	
46.	British	Medical	Association,	Royal	Pharmaceutical	Society	of	Great	Britain.	British	National	Formulary	66th	
Edition.	September	(66)	ed.	London:	BMJ	Group	and	RPS	Publishing;	2013.	
47.	Imamura	H,	Matsuyama	Y,	Tanaka	E,	Ohkubo	T,	Hasegawa	K,	Miyagawa	S,	et	al.	Risk	factors	contributing	to	early	
and	late	phase	intrahepatic	recurrence	of	hepatocellular	carcinoma	after	hepatectomy.	Journal	of	hepatology	
2003;	38(2):200-207.	
48.	Longworth	L,	Young	T,	Buxton	MJ,	Ratcliffe	J,	Neuberger	J,	Burroughs	A,	et	al.	Midterm	cost-effectiveness	of	the	
liver	transplantation	program	of	England	and	Wales	for	three	disease	groups.	Liver	transplantation	:	official	
publication	of	the	American	Association	for	the	Study	of	Liver	Diseases	and	the	International	Liver	Transplantation	
Society	2003;	9(12):1295-1307.	
49.	Ouwens	JP,	van	Enckevort	PJ,	TenVergert	EM,	Bonsel	GJ,	van	der	Bij	W,	Haagsma	EB,	et	al.	The	cost	effectiveness	
of	lung	transplantation	compared	with	that	of	heart	and	liver	transplantation	in	the	Netherlands.	Transplant	
international	:	official	journal	of	the	European	Society	for	Organ	Transplantation	2003;	16(2):123-127.	
50.	Department	of	Health.	NHS	Reference	Costs	2013	to	2014.	In.	London:	Department	of	Health;	2014.	
51.	PSSRU.	Unit	Costs	of	Health	&	Social	Care	2014.	In.	Edited	by	Curtis	L:	Personal	Social	Services	Research	Unit;	
2014.	
52.	The	Information	Centre.	2006/07	UK	General	Practice	Workload	Survey.	In;	2007.	
53.	Stamuli	E.	Cost-effectiveness	of	ultrasound	elastography	in	the	assessment	of	liver	fibrosis.	In:	Centre	for	
Evidence-Based	Purchasing	Economic	Report;	2009.	
54.	Wright	M,	Grieve	R,	Roberts	J,	Main	J,	Thomas	HC,	Investigators	UKMHCT.	Health	benefits	of	antiviral	therapy	
for	mild	chronic	hepatitis	C:	randomised	controlled	trial	and	economic	evaluation.	Health	technology	assessment	
2006;	10(21):1-113,	iii.	
55.	Harman	DJ.	Economic	modelling	of	early	TIPS	insertion	for	acute	variceal	haemorrhage.	(Available	from	authors	
on	request)	2014.	
46	
	
56.	Morling	JR,	Fallowfield	JA,	Guha	IN,	Nee	LD,	Glancy	S,	Williamson	RM,	et	al.	Using	non-invasive	biomarkers	to	
identify	hepatic	fibrosis	in	people	with	type	2	diabetes	mellitus:	the	Edinburgh	type	2	diabetes	study.	Journal	of	
hepatology	2014;	60(2):384-391.	
57.	Chalasani	N,	Younossi	Z,	Lavine	JE,	Diehl	AM,	Brunt	EM,	Cusi	K,	et	al.	The	diagnosis	and	management	of	non-
alcoholic	fatty	liver	disease:	practice	Guideline	by	the	American	Association	for	the	Study	of	Liver	Diseases,	
American	College	of	Gastroenterology,	and	the	American	Gastroenterological	Association.	Hepatology	2012;	
55(6):2005-2023.	
58.	George	K	RS,	Collier	J,	Chapman	R,	Freeman	J.	Management	of	abnormal	LFT	in	asympotmatic	patients.	BSG	
Guidelines.	
59.	Professor	James	Neuberger	DAG,	Professor	Chris	DAy,	Dr	Sushma	Saxseena.	Guidelines	on	the	use	of	Liver	
Biopsy	in	Clinical	Practice.	BSG	Guidelines	in	Gastroenterology.	2004.	
60.	Tripathi.	UK	Guidelines	on	the	management	of	variceal	bleeding	in	cirrhotic	patients.	BSG	guidelines	2015.	
61.	EASL.	EASL-EORTC	Clinical	Practice	Guidelines:	Managment	of	Hepatocellular	Carcinoma.	Journal	of	hepatology	
2012;	Vol.	56:908-943.	
62.	Ratziu	V,	Giral	P,	Jacqueminet	S,	Charlotte	F,	Hartemann-Heurtier	A,	Serfaty	L,	et	al.	Rosiglitazone	for	
nonalcoholic	steatohepatitis:	one-year	results	of	the	randomized	placebo-controlled	Fatty	Liver	Improvement	with	
Rosiglitazone	Therapy	(FLIRT)	Trial.	Gastroenterology	2008;	135(1):100-110.	
63.	NICE.	Alcohol	use	disorders:	diagnosis,	assessment	and	management	of	harful	drinking	and	alcohol	
dependence.	NICE	clinical	guideline	115	2011.	
64.	Moore	KP,	Aithal	GP.	Guidelines	on	the	management	of	ascites	in	cirrhosis.	Gut	2006;	55	Suppl	6:vi1-12.	
65.	American	Association	for	the	Study	of	Liver	D,	European	Association	for	the	Study	of	the	L.	Hepatic	
encephalopathy	in	chronic	liver	disease:	2014	practice	guideline	by	the	European	Association	for	the	Study	of	the	
Liver	and	the	American	Association	for	the	Study	of	Liver	Diseases.	Journal	of	hepatology	2014;	61(3):642-659.	
66.	NICE.	Rifaximin	for	preventing	episodes	of	overt	hepatic	encephalopathy.	NICE	technology	appraisal	guidance	
337	2015.	
67.	Short	JB,	E,	James,	M.	HCC	in	2010;	are	we	offering	the	appropriate	therapy?	BSG	2011	Abstract	submission	
2011.	
68.	D'Amico	G,	Pasta	L,	Morabito	A,	D'Amico	M,	Caltagirone	M,	Malizia	G,	et	al.	Competing	risks	and	prognostic	
stages	of	cirrhosis:	a	25-year	inception	cohort	study	of	494	patients.	Alimentary	pharmacology	&	therapeutics	2014;	
39(10):1180-1193.	
69.	EASL.	EASL-ALEH	Clinical	Practice	Guidelines:	Non-invasive	tests	for	evaluation	of	liver	disease	severity	and	
prognosis.	Journal	of	hepatology	2015;	63(1):237-264.	
70.	NICE.	Alcohol-use	disorders:	alcohol	dependence.	Costing	report.	In;	2011.	
71.	Taylor	MC,	Greig	PD,	Detsky	AS,	McLeod	RS,	Abdoh	A,	Krahn	MD.	Factors	associated	with	the	high	cost	of	liver	
transplantation	in	adults.	Canadian	journal	of	surgery	Journal	canadien	de	chirurgie	2002;	45(6):425-434.	
72.	Filipponi	F,	Pisati	R,	Cavicchini	G,	Ulivieri	MI,	Ferrara	R,	Mosca	F.	Cost	and	outcome	analysis	and	cost	
determinants	of	liver	transplantation	in	a	European	National	Health	Service	hospital.	Transplantation	2003;	
75(10):1731-1736.	
73.	Best	JH,	Veenstra	DL,	Geppert	J.	Trends	in	expenditures	for	Medicare	liver	transplant	recipients.	Liver	
transplantation	:	official	publication	of	the	American	Association	for	the	Study	of	Liver	Diseases	and	the	International	
Liver	Transplantation	Society	2001;	7(10):858-862.	
74.	Lang	K,	Danchenko	N,	Gondek	K,	Shah	S,	Thompson	D.	The	burden	of	illness	associated	with	hepatocellular	
carcinoma	in	the	United	States.	Journal	of	hepatology	2009;	50(1):89-99.	
75.	van	Agthoven	M,	Metselaar	HJ,	Tilanus	HW,	de	Man	RA,	JN	IJ,	Martin	van	Ineveld	BM.	A	comparison	of	the	costs	
and	effects	of	liver	transplantation	for	acute	and	for	chronic	liver	failure.	Transplant	international	:	official	journal	
of	the	European	Society	for	Organ	Transplantation	2001;	14(2):87-94.	
47	
	
76.	van	der	Hilst	CS,	Ijtsma	AJ,	Slooff	MJ,	Tenvergert	EM.	Cost	of	liver	transplantation:	a	systematic	review	and	
meta-analysis	comparing	the	United	States	with	other	OECD	countries.	Medical	care	research	and	review	:	MCRR	
2009;	66(1):3-22.	
77.	Lin	OS,	Keeffe	EB,	Sanders	GD,	Owens	DK.	Cost-effectiveness	of	screening	for	hepatocellular	carcinoma	in	
patients	with	cirrhosis	due	to	chronic	hepatitis	C.	Alimentary	pharmacology	&	therapeutics	2004;	19(11):1159-1172.	
78.	Taylor	MC,	Greig	PD,	Detsky	AS,	McLeod	RS,	Abdoh	A,	Krahn	MD.	Factors	associated	with	the	high	cost	of	liver	
transplantation	in	adults.	Canadian	Journal	of	Surgery	2002;	45(6):425-434.	
79.	Singh	S,	Allen	AM,	Wang	Z,	Prokop	LJ,	Murad	MH,	Loomba	R.	Fibrosis	Progression	in	Nonalcoholic	Fatty	Liver	vs	
Nonalcoholic	Steatohepatitis:	A	Systematic	Review	and	Meta-analysis	of	Paired-Biopsy	Studies.	Clinical	
Gastroenterology	and	Hepatology	2014.	
	
